{"gene":"TREM2","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2006,"finding":"TREM2 signals through the adaptor protein DAP12 and functions to attenuate macrophage activation by inhibiting cytokine production in response to TLR ligands (LPS, zymosan, CpG); TREM2-deficient macrophages produce more cytokines, and TREM2 accounts for the increased cytokine production previously reported in DAP12-deficient macrophages.","method":"TREM2 knockout mice, TLR ligand stimulation assays, cytokine measurement","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular phenotype, genetic epistasis with DAP12, replicated across multiple TLR ligands","pmids":["16951310"],"is_preprint":false},{"year":2007,"finding":"TREM2 transduces intracellular signals through DAP12 and is required for normal osteoclastogenesis; human TREM2/DAP12-deficient pre-osteoclast precursors fail to differentiate into mature osteoclasts with bone resorptive activity in vitro.","method":"In vitro osteoclast differentiation assay with human TREM2/DAP12-deficient precursors","journal":"Advances in experimental medicine and biology","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined cellular differentiation phenotype, single lab","pmids":["17966394"],"is_preprint":false},{"year":2014,"finding":"TREM2 missense mutations associated with FTD and FTD-like syndrome reduce TREM2 maturation, abolish shedding by ADAM proteases (α-secretases), and impair phagocytic activity; as a consequence of reduced shedding, TREM2 is virtually absent in CSF and plasma of affected patients.","method":"Cell-based assays of TREM2 maturation and shedding, phagocytosis assays, CSF/plasma measurement in patients","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (biochemistry, functional phagocytosis, patient biofluid), replicated across mutations","pmids":["24990881"],"is_preprint":false},{"year":2014,"finding":"TREM2 promotes macrophage-mediated intracellular killing of Pseudomonas aeruginosa by enhancing reactive oxygen species (ROS) production via the PI3K/Akt signaling pathway; TREM2 silencing inhibits Akt phosphorylation and bacterial killing, whereas PI3K agonism rescues the killing defect.","method":"TREM2 siRNA knockdown, overexpression, phagocytosis/killing assays, ROS measurement, PI3K inhibitor/agonist treatments, Western blot for Akt phosphorylation","journal":"Scandinavian journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods (KD, OE, pharmacological rescue) in single study","pmids":["24383713"],"is_preprint":false},{"year":2015,"finding":"TREM2 senses a broad array of anionic and zwitterionic lipids (damage-associated lipid patterns) associated with fibrillar Aβ in lipid membranes and on damaged neurons; TREM2 deficiency and haploinsufficiency cause dysfunctional microglial clustering around Aβ plaques and microglial apoptosis in the 5XFAD mouse model; the R47H AD-risk mutation impairs TREM2 detection of lipid ligands.","method":"5XFAD mouse model with TREM2 KO/haploinsufficiency, lipid-binding assays, microglial clustering and apoptosis analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro lipid-binding assays + mouse model with defined cellular phenotype, high-citation foundational paper","pmids":["25728668"],"is_preprint":false},{"year":2015,"finding":"TREM2 promotes macrophage survival; viral replication increases TREM2 levels including the soluble form (sTREM2), and IL-13 and DAP12 promote TREM2 cleavage to sTREM2, which acts in a feed-forward manner to prevent macrophage apoptosis.","method":"Mouse model of Sendai virus infection, TREM2 KO mice, measurement of soluble TREM2, apoptosis assays","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 — KO mouse with defined phenotype plus mechanistic sTREM2 characterization, single lab","pmids":["25897174"],"is_preprint":false},{"year":2016,"finding":"TREM2 binds lipoprotein particles (LDL) and apolipoproteins (APOE, CLU/APOJ) identified by unbiased protein microarray; TREM2 overexpression enhances uptake of LDL, CLU, and APOE; Aβ-lipoprotein complexes are taken up by microglia in a TREM2-dependent fashion; disease-associated TREM2 mutations abolish or reduce ligand binding and impair uptake.","method":"Protein microarray screen, Co-IP/pulldown, overexpression in heterologous cells, Trem2 KO microglia, human macrophage uptake assays","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — unbiased screen + multiple functional uptake assays + KO microglia + human cells with disease variant","pmids":["27477018"],"is_preprint":false},{"year":2017,"finding":"TREM2 deficiency causes defective mTOR signaling, leading to aberrant autophagy, reduced ATP levels, and impaired biosynthetic pathways in microglia; this metabolic derailment can be rescued in vitro by Dectin-1 (which elicits TREM2-like signals) or cyclocreatine, and dietary cyclocreatine restores microglial clustering and reduces neuronal dystrophy in TREM2-deficient AD mice.","method":"Metabolomics + RNA-seq, TREM2-deficient mouse and human AD samples, in vitro rescue experiments, in vivo dietary cyclocreatine treatment","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — metabolomics + transcriptomics + in vitro + in vivo rescue, high-citation paper with orthogonal methods","pmids":["28802038"],"is_preprint":false},{"year":2017,"finding":"TREM2 promotes microglial survival by activating the Wnt/β-catenin signaling pathway; TREM2 stabilizes β-catenin by inhibiting its degradation via Akt/GSK3β; TREM2 deficiency reduces viability and proliferation of primary microglia and induces G1/S cell cycle arrest; treatment with Wnt pathway activators (Wnt3a, LiCl, TDZD-8) rescues microglia survival in Trem2-deficient microglia and brain.","method":"TREM2 KD/KO in vitro and in vivo, cell viability/proliferation assays, β-catenin stability assays, pharmacological rescue with Wnt agonists","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — multiple KD/KO models + defined signaling mechanism + pharmacological rescue in vitro and in vivo","pmids":["28077724"],"is_preprint":false},{"year":2017,"finding":"TREM2 induces APOE signaling and drives a switch from homeostatic to neurodegenerative microglia phenotype after phagocytosis of apoptotic neurons; targeting the TREM2-APOE pathway restores homeostatic microglial signature in ALS and AD mouse models and prevents neuronal loss in acute neurodegeneration models.","method":"Mouse models of ALS, MS, AD; microglial transcriptomics; APOE targeting; genetic and pharmacological manipulation","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — multiple disease models + genetic epistasis + defined pathway + replicated across diseases","pmids":["28930663"],"is_preprint":false},{"year":2018,"finding":"TREM2 directly binds β-amyloid (Aβ) oligomers with nanomolar affinity; TREM2 deficiency impairs Aβ degradation; Aβ-induced microglial responses (depolarization, K+ current, cytokine expression, migration, proliferation, apoptosis, morphological changes) are TREM2-dependent; Aβ enhances TREM2 interaction with DAP12, regulating downstream phosphorylation of SYK and GSK3β.","method":"Direct binding assays, primary microglial culture, mouse brain experiments, Co-IP for TREM2-DAP12, phosphorylation assays for SYK and GSK3β, TREM2 KO mice","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1-2 — binding assays + KO + multiple downstream signaling readouts with orthogonal methods","pmids":["29518356"],"is_preprint":false},{"year":2018,"finding":"TREM2 interacts directly with various forms of Aβ, with highest affinity for soluble Aβ42 oligomers (slow dissociation); Aβ pre-incubation blocks APOE interaction with TREM2; AD-associated TREM2 variants (R47H, R62H) show equivalent Aβ binding affinity but loss-of-function in terms of downstream NFAT signaling and Aβ42 internalization.","method":"Multiple binding assays (SPR, ELISA-based), NFAT reporter assay, Aβ42 internalization assays in cells expressing TREM2 variants","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 1 — in vitro binding reconstitution with multiple assay formats + functional signaling assay","pmids":["30341064"],"is_preprint":false},{"year":2019,"finding":"Loss of functional TREM2 increases amyloid plaque seeding due to reduced microglial clustering around newly seeded plaques and reduced plaque-associated ApoE; microglia are identified as one origin of plaque-associated ApoE; longitudinal PET demonstrates accelerated early amyloidogenesis in Trem2 loss-of-function mutants.","method":"Trem2 KO mouse models, microglia depletion, proteomic analyses of plaques, longitudinal amyloid small-animal PET, human AD brain analysis","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (proteomics, microglia depletion, in vivo imaging, human validation)","pmids":["30617257"],"is_preprint":false},{"year":2019,"finding":"TREM2 is required for TREM2+ lipid-associated macrophage (LAM) transcriptional programming in adipose tissue; genetic ablation of Trem2 inhibits the downstream LAM molecular program, leading to adipocyte hypertrophy, systemic hypercholesterolemia, body fat accumulation, and glucose intolerance.","method":"Single-cell RNA sequencing, Trem2 KO mice, metabolic phenotyping","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — scRNA-seq + KO with defined metabolic phenotype, high-citation paper","pmids":["31257031"],"is_preprint":false},{"year":2019,"finding":"TREM2 acts downstream of CD33 in modulating microglial function: CD33 knockout reduces Aβ pathology in an effect that requires TREM2; genes related to phagocytosis and signaling upregulated in 5xFAD;CD33-/- microglia depend on the presence of TREM2, establishing TREM2 downstream of CD33 by genetic epistasis.","method":"Double-knockout mouse models (5xFAD;CD33-/-;TREM2-/-), RNA-seq profiling, epistasis analysis","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with multiple KO combinations + transcriptomics","pmids":["31301936"],"is_preprint":false},{"year":2020,"finding":"TREM2-deficient microglia phagocytose myelin debris but fail to clear myelin cholesterol, resulting in pathogenic cholesteryl ester (CE) accumulation; TREM2 acts as a key transcriptional regulator of cholesterol transport and metabolism; CE accumulation is rescued by ACAT1 inhibitor and LXR agonist.","method":"Chronic demyelination mouse model, TREM2 KO mice, RNA-seq + lipidomics, human iPSC-derived microglia, pharmacological rescue","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 1-2 — RNA-seq + lipidomics + mouse model + human iPSC microglia + pharmacological rescue","pmids":["31902528"],"is_preprint":false},{"year":2020,"finding":"Genetic ablation of Trem2 in tumor-bearing mice inhibits accumulation of intra-tumoral Arg1+ Trem2+ regulatory myeloid (Mreg) cells, leading to decreased dysfunctional CD8+ T cells and reduced tumor growth, identifying TREM2 as a driver of the immunosuppressive myeloid program in tumors.","method":"INs-seq (scRNA-seq + intracellular protein activity), Trem2 KO mouse tumor models, CD8+ T cell functional analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — novel technology + KO with defined immune phenotype in multiple tumor models","pmids":["32783915"],"is_preprint":false},{"year":2020,"finding":"Monoclonal antibody 4D9 targeting the TREM2 stalk region stabilizes TREM2 on the cell surface, reduces ADAM10/17-mediated shedding, and concomitantly activates phospho-SYK signaling; in vivo, 4D9 reduced amyloidogenesis and enhanced microglial TREM2 expression in AD mouse model.","method":"Antibody panel screening, surface TREM2 quantification, phospho-SYK assay, in vitro phagocytosis assays, in vivo AD mouse model treatment","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 2 — mechanistic antibody characterization + in vitro signaling + in vivo validation","pmids":["32154671"],"is_preprint":false},{"year":2021,"finding":"TREM2 recognizes non-glycosylated mycolic acids (MAs) from mycobacteria via a TREM2/DAP12-dependent but CARD9-independent mechanism; this suppresses anti-mycobacterial immunity by recruiting iNOS-negative, mycobacterium-permissive macrophages; TREM2 deletion enhances Mincle-induced macrophage activation and accelerates mycobacterial elimination, indicating TREM2 is exploited by mycobacteria for immune evasion.","method":"Lipid-binding assays, TREM2/DAP12 KO macrophages, in vitro macrophage activation assays, in vivo mycobacterial infection models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — direct ligand binding + KO macrophages + in vivo infection model with defined phenotype","pmids":["33863908"],"is_preprint":false},{"year":2021,"finding":"TREM2 directly interacts with TDP-43 as demonstrated by mass spectrometry and surface plasmon resonance (SPR) in vitro and in vivo; TREM2 deficiency impairs phagocytic clearance of pathological TDP-43 by microglia and enhances neuronal damage; a TREM2-dependent CD11c-high microglial subpopulation with phagocytic activity is induced by human TDP-43.","method":"Mass spectrometry, SPR analysis, TREM2-deficient mouse models, mass cytometry, human ALS tissue analysis","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 1 — SPR for direct binding + MS + KO mouse with phenotype + human tissue validation","pmids":["34916658"],"is_preprint":false},{"year":2021,"finding":"The R47H TREM2 variant induces hyperactivation of AKT signaling downstream of TREM2; pharmacological AKT inhibition (MK-2206) largely reverses enhanced inflammatory signatures in primary R47H microglia and rescues tauopathy-induced synapse loss in R47H heterozygous tauopathy mice.","method":"Human AD snRNA-seq, R47H knock-in tauopathy mouse model, scRNA-seq, pharmacological AKT inhibition with MK-2206","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 — human AD transcriptomics + knock-in mouse model + pharmacological rescue, conserved across species","pmids":["34851693"],"is_preprint":false},{"year":2021,"finding":"TREM2 interacts with TMEM59 (a type I transmembrane protein); TREM2 overexpression reduces TMEM59 protein levels by promoting its degradation; elevated TMEM59 in Trem2-deficient microglia contributes to impaired survival, proliferation, migration, phagocytosis, dysregulated autophagy, and metabolism.","method":"Co-IP, overexpression and KO in microglia, protein degradation assays, functional microglial assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP + functional rescue by TMEM59 silencing, single lab","pmids":["32826884"],"is_preprint":false},{"year":2022,"finding":"TREM2 deletion enhances tau spreading from the medial entorhinal cortex to hippocampus; Trem2 deletion in microglia enhances intraneuronal tau dispersion via exosomes — Trem2 KO microglia show enhanced tau distribution to endosomal/pre-exosomal compartments and exosomes from Trem2 KO microglia have elevated tau levels and enhanced tau-seeding capacity.","method":"AAV-P301L tau injection model, Trem2 KO mice, microfluidic dispersion assay, exosome isolation and characterization, tau FRET reporter assay, proteomic analysis","journal":"Molecular neurodegeneration","confidence":"High","confidence_rationale":"Tier 2 — multiple in vitro and in vivo methods + FRET reporter assay for tau seeding","pmids":["36056435"],"is_preprint":false},{"year":2022,"finding":"LILRB2 (an inhibitory receptor with ITIM motifs) co-ligates with TREM2 on shared ligands (Aβ oligomers, phosphatidylserine) and inhibits TREM2 signaling; a LILRB2 antagonist antibody (Ab29) blocks this inhibition, enhancing TREM2 signaling, microglia phagocytosis, migration, and amyloid plaque clearance in vivo in 5XFAD mice.","method":"Co-ligation experiments in iPSC-derived microglia, LILRB2 antagonist antibody, phagocytosis and migration assays, in vivo stereotaxic microglia grafting in 5XFAD mice","journal":"Molecular neurodegeneration","confidence":"High","confidence_rationale":"Tier 2 — mechanistic co-ligation + antibody rescue in human iPSC microglia + in vivo validation","pmids":["35717259"],"is_preprint":false},{"year":2022,"finding":"TREM2-deficient microglia in TREM2-independent microgliosis context (with ApoE4) show exacerbated tau-mediated neurodegeneration; this is epistatic to ApoE4 — TREM2 KO in P301S/ApoE4 mice worsens, rather than attenuates, neurodegeneration, revealing that TREM2-independent microgliosis facilitates neurodegeneration in the presence of ApoE4.","method":"Double-mutant mouse models (P301S tau × ApoE4 × TREM2 KO), transcriptomics, neuropathology","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with multiple KO combinations in well-defined mouse models","pmids":["36368315"],"is_preprint":false},{"year":2023,"finding":"TREM2 expression in microglia is required for normal bioenergetic profile of pyramidal neurons during development; in Trem2 KO mice, developing CA1 hippocampal neurons display compromised energetic metabolism, reduced mitochondrial mass, abnormal organelle ultrastructure, and delayed neuronal maturation.","method":"Trem2 KO mice, metabolic profiling, electron microscopy of mitochondria, single-cell/nucleus transcriptomics, hippocampal subfield-specific analysis","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — KO mice + ultrastructural analysis + transcriptomics + metabolic profiling with specific regional phenotype","pmids":["38159572"],"is_preprint":false},{"year":2023,"finding":"TREM2 splice isoforms (TREM2-222 and TREM2-219) lacking a transmembrane domain are translated and secreted as soluble TREM2 (sTREM2); all sTREM2 species inhibit long-term potentiation (LTP) induction in hippocampal brain slices, and this effect is abolished by GABAA receptor antagonist picrotoxin.","method":"In vitro translation and secretion assays, LTP electrophysiology in hippocampal slices, pharmacological blockade with picrotoxin","journal":"Genome medicine","confidence":"Medium","confidence_rationale":"Tier 1-2 — in vitro reconstitution + electrophysiology with pharmacological dissection, single lab","pmids":["36805764"],"is_preprint":false},{"year":2023,"finding":"Poly-GA proteins (from C9orf72 GGGGCC repeats) activate the microglial NLRP3 inflammasome to produce IL-1β, which promotes ADAM10-mediated TREM2 cleavage and inhibits phagocytosis of poly-GA; NLRP3 inhibitor MCC950 reduces TREM2 cleavage and poly-GA aggregates, alleviating motor deficits in poly-GA mice.","method":"Mouse model of poly-GA aggregation, NLRP3 inhibitor treatment (MCC950), ADAM10 cleavage assays, phagocytosis assays, motor behavioral testing","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway with pharmacological intervention in vivo + defined ADAM10/TREM2 cleavage assay","pmids":["36800288"],"is_preprint":false},{"year":2023,"finding":"TREM2 mediates phagocytosis of glioma cells via SYK signaling; TREM2+ myeloid cells display enhanced tumor uptake compared to TREM2- cells, and this phagocytic function is mechanistically linked to TREM2-SYK axis.","method":"Single-cell RNA-seq, flow cytometry, in vivo glioma models, in vitro phagocytosis assays with SYK inhibition","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2-3 — in vitro mechanistic assay + in vivo model + human scRNA-seq correlation","pmids":["38237157"],"is_preprint":false},{"year":2023,"finding":"TREM2 macrophages suppress NK cell accumulation and cytolytic activity in lung tumors by modulating IL-18/IL-18BP decoy interactions and IL-15 production; Trem2 genetic deletion rescues NK cell accumulation and enables NK cell-mediated tumor regression.","method":"Murine lung adenocarcinoma model, Trem2 KO mice, NK cell functional assays, cytokine analysis (IL-18, IL-18BP, IL-15)","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — KO mice + defined molecular mechanism (cytokine axis) + functional NK cell readout","pmids":["37081148"],"is_preprint":false},{"year":2023,"finding":"TREM2 is required for antiviral defense in microglia: TREM2 is important for virus-induced IFNB induction through the DNA-sensing cGAS-STING pathway and for phagocytosis of HSV1-infected neurons; TREM2 augments STING signaling and activation of downstream TBK1 and IRF3; TREM2 depletion increases susceptibility to HSV1 infection.","method":"hiPSC-derived microglia, TREM2 depletion, HSV1 infection assays, cGAS-STING pathway analysis, microglia-neuron cocultures, mouse brain infection model","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 — KD in human iPSC microglia + defined signaling pathway + in vivo mouse model","pmids":["37595041"],"is_preprint":false},{"year":2023,"finding":"TREM2hi cardiac resident macrophages actively scavenge cardiomyocyte-ejected dysfunctional mitochondria; Trem2 deficiency in macrophages impairs the self-renewal of this subpopulation and results in defective elimination of damaged mitochondria, excessive inflammation, exacerbated cardiac dysfunction, and decreased survival in sepsis.","method":"Single-cell RNA-seq, fate mapping, Trem2 KO mouse model of sepsis, mitochondria scavenging assays, intrapericardial cell transfer experiments","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 — scRNA-seq + fate mapping + KO + cell transfer rescue, multiple orthogonal methods","pmids":["36635449"],"is_preprint":false},{"year":2023,"finding":"TREM2 deficiency restricts the emergence of lipid-associated macrophages (LAMs) and formation of hepatic crown-like structures; TREM2+ macrophages are superior collagen degraders and required for MASH fibrosis regression; TREM2 imparts protection through phagocytosis, lipid handling, and collagen degradation.","method":"scRNA-seq of mouse MASH progression/regression, Trem2 KO mice, collagen degradation assays, lipid handling assays","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 — scRNA-seq + KO + functional in vitro assays, orthogonal approaches","pmids":["39172787"],"is_preprint":false},{"year":2023,"finding":"Microglia gravitate toward amyloid plaques through TREM2 recognition of externalized phosphatidylserine (ePtdSer) on dystrophic neurons surrounding Aβ plaques; TREM2 loss-of-function (frameshift mutation in exon 2) organoids show reduced TREM2 levels and impaired phagocytic activity toward ePtdSer-positive Aβ plaques.","method":"2D/3D/4D co-culture systems, brain organoids with TREM2 loss-of-function mutations, CRISPR-Cas9 APOE4 lines, APPNL-G-F/MAPT double knock-in mice, live imaging of microglial migration","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 — functional assay in engineered organoid system + mouse models, single lab","pmids":["38981007"],"is_preprint":false},{"year":2024,"finding":"TREM2 in macrophages regulates foamy macrophage specification and oxLDL uptake in atherosclerosis; Trem2 loss reduces foamy macrophage ability to take up oxLDL; mechanistically, Trem2-deficient macrophages fail to upregulate cholesterol efflux molecules, resulting in impaired proliferation and survival; myeloid-specific Trem2 deletion attenuates plaque progression.","method":"Integrated scRNA-seq trajectory analysis, genome-wide CRISPR screen, myeloid-specific Trem2 KO mice, cholesterol efflux assays, oxLDL uptake assays","journal":"Nature cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 — CRISPR screen + KO mouse + functional lipid assays, multiple orthogonal methods","pmids":["38646596"],"is_preprint":false},{"year":2024,"finding":"TREM2 promotes cholesterol uptake and foam cell formation in atherosclerosis by inhibiting p38 MAPK phosphorylation and PPARγ phosphorylation, thereby increasing PPARγ nuclear transcriptional activity and promoting CD36 scavenger receptor transcription; TREM2 overexpression in SMCs and macrophages increases CD36-dependent lipid influx.","method":"ApoE-/- and Trem2-/-/ApoE-/- double KO mice, TREM2 overexpression in primary cells, Western blot for p38/PPARγ phosphorylation, CD36 promoter activity assays","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 — KO mouse + overexpression + defined signaling mechanism, single lab","pmids":["37133566"],"is_preprint":false},{"year":2024,"finding":"TREM2 is essential for efferocytosis capacity of macrophages and survival of lipid-laden macrophages in atherosclerotic lesions; TREM2 deficiency increased necrotic core formation; TREM2 agonism decreased necrotic core formation in early atherosclerosis.","method":"Hematopoietic and global TREM2 KO mice in atherosclerosis model, TREM2 agonist treatment, efferocytosis assays, plaque analysis","journal":"Nature cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 — KO + agonism + functional efferocytosis assays in vivo and in vitro","pmids":["38974464"],"is_preprint":false},{"year":2024,"finding":"CNS-enriched sphingolipids bind TREM2 on myeloid cells in GBM and elicit antitumor responses; TREM2 is immunoprotective in GBM (opposite to peripheral cancers), negatively correlating with immunosuppressive signatures; TREM2 deficiency promotes GBM progression, while AAV-mediated TREM2 overexpression impedes GBM progression.","method":"Genetic/pharmacological TREM2 deficiency in vivo, scRNA-seq and spatial sequencing, sphingolipid-TREM2 binding assays, AAV-TREM2 overexpression, anti-PD-1 combination therapy","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — direct lipid binding + multiple in vivo KO/OE models + single-cell sequencing, orthogonal methods","pmids":["38788719"],"is_preprint":false},{"year":2024,"finding":"TREM2 promotes macrophage metabolic reprogramming after efferocytosis through the SYK-SMAD4 signaling pathway, which decreases SLC25A53 transcription, impairing NAD+ transport into mitochondria and causing a TCA cycle breakpoint that increases itaconate production; secreted itaconate from TREM2+ macrophages inhibits cardiomyocyte apoptosis and promotes fibroblast proliferation after myocardial infarction.","method":"RNA-seq, molecular docking, targeted metabolomics (LC-MS), macrophage-specific TREM2 KO mice, in vitro co-culture experiments","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 — metabolomics + RNA-seq + molecular docking + KO mice, single lab with multiple methods","pmids":["38182899"],"is_preprint":false},{"year":2024,"finding":"TREM2 deficiency in Schwann cells disrupts glycolytic flux and oxidative metabolism, impairs cell proliferation, triggers mitochondrial damage and autophagy via AMPK activation and impaired PI3K-AKT-mTOR signaling; TREM2 deficiency also impairs energy metabolism and axonal growth in sciatic nerve and exacerbates neurological deficits in a mouse model of acute motor axonal neuropathy.","method":"TREM2-deficient Schwann cells, metabolomic analysis, AMPK/PI3K-AKT-mTOR pathway analysis, mouse model of AMAN, nerve regeneration assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — metabolomics + signaling pathway analysis + in vivo neuropathy model, single lab","pmids":["38453910"],"is_preprint":false},{"year":2025,"finding":"TREM2 functions as a key braking mechanism for the NLRP3/NF-κB/IL-1β inflammasome pathway in tumor-associated macrophages; TREM2 depletion combined with microbial LPS triggers IL-1β upregulation and pathogenic inflammation that fuels pancreatic cancer development; IL-1β inhibition or microbiome ablation reverses accelerated PDAC progression caused by TREM2 depletion.","method":"KPPC;Trem2-/- transgenic mouse model of spontaneous PDAC, scRNA-seq, IL-1β inhibition, microbiome ablation experiments","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — genetic mouse model + scRNA-seq + pharmacological and microbiome rescue, multiple orthogonal approaches","pmids":["39956331"],"is_preprint":false}],"current_model":"TREM2 is a myeloid cell surface receptor that signals through the adaptor proteins DAP12 (and DAP10) upon binding diverse ligands including anionic lipids, apolipoproteins (APOE, CLU), Aβ oligomers, TDP-43, phosphatidylserine, sphingolipids, and mycolic acids; ligand engagement triggers intracellular SYK phosphorylation and downstream activation of PI3K/Akt, mTOR, Wnt/β-catenin, and AKT/GSK3β pathways, which collectively regulate microglial/macrophage phagocytosis, metabolic fitness (mTOR-dependent energy metabolism and cholesterol handling), survival, proliferation, and inflammatory tone; TREM2 is shed from the cell surface by ADAM10/17 α-secretases to generate soluble sTREM2, and disease-associated mutations (R47H, R62H) impair ligand sensing, TREM2 maturation/shedding, and downstream signaling, thereby impairing the microglial response to Aβ plaques, myelin debris, and other damage-associated patterns across neurodegenerative diseases, metabolic disorders, and cancer."},"narrative":{"teleology":[{"year":2006,"claim":"Establishing TREM2 as an anti-inflammatory brake: TREM2 signals through DAP12 to attenuate TLR-induced cytokine production in macrophages, resolving the question of why DAP12-deficient macrophages are hyperinflammatory.","evidence":"TREM2 KO macrophages stimulated with multiple TLR ligands; epistasis with DAP12 KO","pmids":["16951310"],"confidence":"High","gaps":["Ligand identity for TREM2 unknown at this point","Mechanism of cytokine suppression downstream of DAP12 unresolved","Tissue-specific roles beyond macrophages untested"]},{"year":2007,"claim":"Demonstrating TREM2/DAP12 signaling is required for osteoclast differentiation extended TREM2 function beyond inflammation to myeloid cell fate decisions.","evidence":"In vitro osteoclastogenesis from human TREM2/DAP12-deficient precursors","pmids":["17966394"],"confidence":"Medium","gaps":["Single in vitro system without in vivo bone phenotype characterization","Downstream differentiation signals not identified","Unclear if TREM2 vs DAP12 deficiency is rate-limiting"]},{"year":2014,"claim":"Linking disease mutations to molecular mechanism: FTD-associated TREM2 missense mutations abolish ADAM protease-mediated shedding, reduce maturation, and impair phagocytosis, explaining the near-absence of sTREM2 in patient biofluids.","evidence":"Cell-based TREM2 maturation/shedding assays, phagocytosis assays, CSF/plasma sTREM2 measurement in patients","pmids":["24990881"],"confidence":"High","gaps":["Identity of ADAM10 vs ADAM17 as dominant sheddase not disambiguated","Whether shedding loss is cause or correlate of neurodegeneration unclear"]},{"year":2014,"claim":"Identifying PI3K/Akt as a key intracellular effector: TREM2 promotes bacterial killing through PI3K/Akt-dependent ROS production, establishing the first defined signaling axis downstream of TREM2.","evidence":"siRNA knockdown and overexpression in macrophages, PI3K agonist rescue of killing defect","pmids":["24383713"],"confidence":"Medium","gaps":["Single pathogen system","No direct demonstration of TREM2–PI3K physical interaction","SYK involvement not yet tested"]},{"year":2015,"claim":"Identifying TREM2's physiological ligands: TREM2 senses anionic and zwitterionic lipids on damaged neurons and Aβ-associated membranes; TREM2 deficiency causes failed microglial clustering around plaques and microglial apoptosis in AD mice, with R47H impairing lipid detection.","evidence":"Lipid-binding assays, 5XFAD mice with TREM2 KO/haploinsufficiency, microglial imaging","pmids":["25728668"],"confidence":"High","gaps":["Structural basis of lipid recognition unknown","Which specific lipid species dominate in vivo undetermined","Contribution of protein vs lipid ligands to in vivo phenotype unclear"]},{"year":2015,"claim":"sTREM2 identified as a bioactive species: IL-13 and DAP12 promote TREM2 cleavage, and the resulting sTREM2 acts in a feed-forward manner to prevent macrophage apoptosis during viral infection.","evidence":"TREM2 KO mice with Sendai virus, sTREM2 measurement, apoptosis assays","pmids":["25897174"],"confidence":"Medium","gaps":["Receptor for sTREM2 not identified","Single viral infection model","Whether sTREM2 signals through same or different receptor unclear"]},{"year":2016,"claim":"Apolipoprotein binding expanded TREM2 ligand repertoire: unbiased screen identified APOE and CLU as TREM2 ligands; TREM2 mediates uptake of Aβ-lipoprotein complexes, and disease mutations impair this binding and uptake.","evidence":"Protein microarray, Co-IP, overexpression uptake assays, Trem2 KO microglia, human macrophage assays","pmids":["27477018"],"confidence":"High","gaps":["Whether TREM2 binds lipidated vs free APOE differently not resolved","Relative contribution of lipid vs protein moieties in lipoprotein recognition unclear"]},{"year":2017,"claim":"Three converging studies established TREM2's role in microglial metabolic fitness, survival via Wnt/β-catenin, and the TREM2-APOE axis for microglial state switching: TREM2 deficiency causes mTOR-dependent metabolic derailment with reduced ATP and aberrant autophagy; TREM2 stabilizes β-catenin via Akt/GSK3β to promote survival; and TREM2 drives APOE signaling to switch microglia from homeostatic to neurodegenerative phenotype.","evidence":"Metabolomics/RNA-seq with cyclocreatine rescue in AD mice; β-catenin stability and Wnt agonist rescue in KO microglia; transcriptomics in ALS/AD/MS mouse models with APOE pathway targeting","pmids":["28802038","28077724","28930663"],"confidence":"High","gaps":["How TREM2 engages mTOR mechanistically not fully resolved","Whether Wnt/β-catenin and mTOR axes operate independently or converge unclear","Causal direction between TREM2 and APOE induction in disease not established"]},{"year":2018,"claim":"Direct nanomolar Aβ binding and signaling cascade defined: TREM2 binds Aβ oligomers directly with high affinity; engagement enhances TREM2-DAP12 association and triggers SYK/GSK3β phosphorylation; R47H/R62H variants retain Aβ binding but lose downstream signaling and internalization capacity.","evidence":"SPR, ELISA, NFAT reporter, internalization assays, Co-IP for TREM2-DAP12, phosphorylation assays in KO microglia","pmids":["29518356","30341064"],"confidence":"High","gaps":["Structural basis of how R47H retains Aβ binding yet loses signaling unknown","Relative importance of Aβ vs lipid ligands in AD pathogenesis not resolved"]},{"year":2019,"claim":"TREM2 established as a master regulator of lipid-associated macrophage (LAM) programs and amyloid plaque containment: TREM2 loss increases amyloid seeding due to failed microglial plaque barrier; in adipose tissue, TREM2 is required for LAM transcriptional programming, and its loss causes metabolic syndrome.","evidence":"Trem2 KO mice with longitudinal amyloid PET and plaque proteomics; scRNA-seq of adipose macrophages with metabolic phenotyping; genetic epistasis with CD33","pmids":["30617257","31257031","31301936"],"confidence":"High","gaps":["Whether LAM programming is identical across tissues undetermined","CD33-TREM2 physical interaction not demonstrated","Whether metabolic phenotype is cell-autonomous or paracrine unclear"]},{"year":2020,"claim":"TREM2 controls cholesterol metabolism after myelin phagocytosis and shapes tumor immunity: TREM2-deficient microglia accumulate toxic cholesteryl esters after demyelination; in tumors, TREM2 drives immunosuppressive myeloid programming that suppresses CD8+ T cell function; anti-TREM2 antibody 4D9 stabilizes surface TREM2 and activates SYK signaling in vivo.","evidence":"RNA-seq/lipidomics with iPSC microglia and demyelination model; INs-seq in Trem2 KO tumor models; antibody characterization with phospho-SYK and in vivo AD model treatment","pmids":["31902528","32783915","32154671"],"confidence":"High","gaps":["Whether cholesterol handling defect is specific to myelin-derived cholesterol unknown","Tumor context-dependency of TREM2 immunosuppressive role not explained mechanistically","Long-term in vivo effects of anti-shedding antibodies not assessed"]},{"year":2021,"claim":"Expanding ligand repertoire and variant signaling: TREM2 directly binds mycolic acids and TDP-43, and R47H hyperactivates AKT, which can be therapeutically targeted to rescue tauopathy-associated synapse loss.","evidence":"SPR/MS for TDP-43 binding with KO mice; lipid-binding assays for mycolic acids with in vivo mycobacterial infection; R47H knock-in tauopathy mice with AKT inhibitor MK-2206 rescue","pmids":["33863908","34916658","34851693"],"confidence":"High","gaps":["Whether TDP-43 is a physiological TREM2 ligand in living brain unclear","How R47H causes AKT hyperactivation while losing other signaling functions paradoxical and unresolved","TMEM59 interaction validation limited to single Co-IP study"]},{"year":2022,"claim":"TREM2 constrains tau spreading and is counter-regulated by LILRB2: TREM2 deletion enhances exosome-mediated tau propagation; LILRB2 co-ligates with TREM2 on shared ligands to inhibit TREM2 signaling, and LILRB2 blockade rescues microglial phagocytosis and plaque clearance.","evidence":"AAV-tau injection in Trem2 KO mice with exosome tau FRET reporter; LILRB2 antagonist antibody in iPSC microglia and 5XFAD mice","pmids":["36056435","35717259"],"confidence":"High","gaps":["Whether LILRB2-TREM2 crosstalk operates in non-AD contexts unknown","Mechanism by which TREM2 controls exosome tau sorting not identified","ApoE4 epistasis with TREM2 in tau spreading not fully resolved"]},{"year":2023,"claim":"TREM2 function extended to cardiac, hepatic, antiviral, developmental, and tumor contexts: TREM2+ cardiac macrophages scavenge damaged mitochondria; TREM2 is required for MASH fibrosis regression via collagen degradation; TREM2 augments cGAS-STING antiviral signaling; TREM2 is needed for neuronal metabolic maturation during development; and TREM2+ macrophages suppress NK cells in lung tumors via IL-18BP/IL-15 axis.","evidence":"Trem2 KO in sepsis/cardiac models, MASH regression models with scRNA-seq, iPSC microglia with HSV1 infection, developmental Trem2 KO with electron microscopy and metabolomics, lung adenocarcinoma KO models","pmids":["36635449","39172787","37595041","38159572","37081148"],"confidence":"High","gaps":["Whether cardiac and hepatic TREM2 ligands differ from CNS ligands unknown","cGAS-STING augmentation mechanism not defined at the molecular level","How microglial TREM2 non-cell-autonomously controls neuronal mitochondria during development unclear"]},{"year":2023,"claim":"sTREM2 splice isoforms and NLRP3-driven shedding revealed new regulatory layers: alternatively spliced TREM2 isoforms lacking transmembrane domains are secreted and inhibit LTP via a GABAA-dependent mechanism; poly-GA aggregates activate NLRP3/IL-1β to promote ADAM10-mediated TREM2 shedding.","evidence":"In vitro translation/secretion assays, hippocampal slice LTP with picrotoxin rescue; poly-GA mouse model with NLRP3 inhibitor MCC950","pmids":["36805764","36800288"],"confidence":"Medium","gaps":["Receptor for sTREM2 in LTP modulation unidentified","Mechanism linking sTREM2 to GABAA signaling unknown","Whether NLRP3-driven shedding is generalizable beyond C9orf72 context unclear"]},{"year":2024,"claim":"TREM2 in cardiovascular disease and cancer refined: TREM2 programs foamy macrophage specification and efferocytosis in atherosclerosis; TREM2 drives post-efferocytosis metabolic reprogramming via SYK-SMAD4-itaconate in myocardial infarction; CNS-enriched sphingolipids activate TREM2 to mount anti-tumor responses in GBM, opposite to peripheral tumors.","evidence":"CRISPR screens and myeloid-specific KO in atherosclerosis; metabolomics with macrophage-specific KO in MI; sphingolipid binding assays with AAV-TREM2 in GBM models","pmids":["38646596","38974464","38182899","38788719"],"confidence":"High","gaps":["Structural determinants of sphingolipid vs other lipid recognition not resolved","Why TREM2 is immunosuppressive in peripheral tumors but immunoprotective in GBM remains mechanistically unexplained","Whether itaconate production is a universal post-efferocytosis output unclear"]},{"year":2025,"claim":"TREM2 identified as a key brake on NLRP3/NF-κB/IL-1β inflammasome in tumor-associated macrophages: TREM2 depletion combined with microbial LPS unleashes IL-1β-driven pathogenic inflammation that accelerates pancreatic cancer.","evidence":"KPPC;Trem2-/- spontaneous PDAC model with scRNA-seq, IL-1β inhibition and microbiome ablation rescue","pmids":["39956331"],"confidence":"High","gaps":["Whether TREM2 directly inhibits NLRP3 assembly or acts upstream unclear","Microbiome composition changes in TREM2 KO not defined","Generalizability to other GI cancers untested"]},{"year":null,"claim":"Key unresolved questions include: the structural basis of TREM2's promiscuous ligand recognition; the receptor and signaling mechanism for soluble sTREM2; why TREM2 exerts opposing immunological roles in CNS versus peripheral tumors; and how TREM2 non-cell-autonomously regulates neuronal metabolism during development.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of TREM2 with lipid or protein ligands","sTREM2 receptor unknown","Tissue-context determinants of pro- vs anti-inflammatory TREM2 output undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,4,10,11]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[4,18,37]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,16,40]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[6,15,34]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,4,10,17]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,5,26]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,16,18,29,30]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,7,8,10,20]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[7,15,34,35]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4,5,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[12,22,24]}],"complexes":["TREM2/DAP12"],"partners":["TYROBP","APOE","CLU","SYK","ADAM10","LILRB2","TMEM59"],"other_free_text":[]},"mechanistic_narrative":"TREM2 is a myeloid cell surface receptor that senses diverse damage- and pathogen-associated molecular patterns—including anionic lipids, apolipoproteins (APOE, CLU), amyloid-β oligomers, TDP-43, phosphatidylserine, sphingolipids, and mycolic acids—and transduces signals through the adaptor DAP12 to activate SYK, PI3K/Akt, mTOR, and Wnt/β-catenin pathways, thereby governing macrophage and microglial phagocytosis, survival, proliferation, metabolic fitness, and inflammatory calibration [PMID:25728668, PMID:29518356, PMID:28802038, PMID:28077724, PMID:16951310]. TREM2 is proteolytically shed by ADAM10/17 to generate soluble sTREM2, and disease-associated mutations (R47H, R62H) impair ligand binding, receptor maturation/shedding, and downstream signaling, disrupting microglial barrier function around amyloid plaques and myelin debris [PMID:24990881, PMID:30341064, PMID:32154671]. Beyond the CNS, TREM2 programs lipid-associated macrophage (LAM) transcriptional states required for cholesterol handling and efferocytosis in adipose tissue, atherosclerotic lesions, and liver fibrosis, and it modulates anti-tumor immunity in a tissue-context-dependent manner—immunosuppressive in peripheral tumors yet immunoprotective in glioblastoma [PMID:31257031, PMID:38974464, PMID:32783915, PMID:38788719]. Loss-of-function TREM2 mutations cause Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy) and frontotemporal dementia-like syndromes, and the R47H variant is a major genetic risk factor for Alzheimer's disease [PMID:24990881, PMID:34851693]."},"prefetch_data":{"uniprot":{"accession":"Q9NZC2","full_name":"Triggering receptor expressed on myeloid cells 2","aliases":["Triggering receptor expressed on monocytes 2"],"length_aa":230,"mass_kda":25.4,"function":"Forms a receptor signaling complex with TYROBP which mediates signaling and cell activation following ligand binding (PubMed:10799849). Acts as a receptor for amyloid-beta protein 42, a cleavage product of the amyloid-beta precursor protein APP, and mediates its uptake and degradation by microglia (PubMed:27477018, PubMed:29518356). Binding to amyloid-beta 42 mediates microglial activation, proliferation, migration, apoptosis and expression of pro-inflammatory cytokines, such as IL6R and CCL3, and the anti-inflammatory cytokine ARG1 (By similarity). Acts as a receptor for lipoprotein particles such as LDL, VLDL, and HDL and for apolipoproteins such as APOA1, APOA2, APOB, APOE, APOE2, APOE3, APOE4, and CLU and enhances their uptake in microglia (PubMed:27477018). Binds phospholipids (preferably anionic lipids) such as phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol and sphingomyelin (PubMed:29794134). Regulates microglial proliferation by acting as an upstream regulator of the Wnt/beta-catenin signaling cascade (By similarity). Required for microglial phagocytosis of apoptotic neurons (PubMed:24990881). Also required for microglial activation and phagocytosis of myelin debris after neuronal injury and of neuronal synapses during synapse elimination in the developing brain (By similarity). Regulates microglial chemotaxis and process outgrowth, and also the microglial response to oxidative stress and lipopolysaccharide (By similarity). It suppresses PI3K and NF-kappa-B signaling in response to lipopolysaccharide; thus promoting phagocytosis, suppressing pro-inflammatory cytokine and nitric oxide production, inhibiting apoptosis and increasing expression of IL10 and TGFB (By similarity). During oxidative stress, it promotes anti-apoptotic NF-kappa-B signaling and ERK signaling (By similarity). Plays a role in microglial MTOR activation and metabolism (By similarity). Regulates age-related changes in microglial numbers (PubMed:29752066). Triggers activation of the immune responses in macrophages and dendritic cells (PubMed:10799849). Mediates cytokine-induced formation of multinucleated giant cells which are formed by the fusion of macrophages (By similarity). In dendritic cells, receptor of SEMA6D with PLEXNA1 as coreceptor and mediates up-regulation of chemokine receptor CCR7 and dendritic cell maturation and survival (PubMed:11602640). Involved in the positive regulation of osteoclast differentiation (PubMed:12925681)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q9NZC2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TREM2","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TREM2","total_profiled":1310},"omim":[{"mim_id":"620845","title":"TRANSMEMBRANE 4 L6 FAMILY, MEMBER 19; TM4SF19","url":"https://www.omim.org/entry/620845"},{"mim_id":"618193","title":"POLYCYSTIC LIPOMEMBRANOUS OSTEODYSPLASIA WITH SCLEROSING LEUKOENCEPHALOPATHY 2; PLOSL2","url":"https://www.omim.org/entry/618193"},{"mim_id":"615080","title":"ALZHEIMER DISEASE 17; AD17","url":"https://www.omim.org/entry/615080"},{"mim_id":"609716","title":"TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-LIKE PROTEIN 3; TREML3","url":"https://www.omim.org/entry/609716"},{"mim_id":"609715","title":"TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-LIKE PROTEIN 2; TREML2","url":"https://www.omim.org/entry/609715"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Vesicles","reliability":"Uncertain"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":58.6},{"tissue":"choroid plexus","ntpm":55.1}],"url":"https://www.proteinatlas.org/search/TREM2"},"hgnc":{"alias_symbol":["TREM-2","Trem2a","Trem2b","Trem2c"],"prev_symbol":[]},"alphafold":{"accession":"Q9NZC2","domains":[{"cath_id":"2.60.40.10","chopping":"17-132","consensus_level":"medium","plddt":95.1626,"start":17,"end":132}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NZC2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NZC2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NZC2-F1-predicted_aligned_error_v6.png","plddt_mean":76.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TREM2","jax_strain_url":"https://www.jax.org/strain/search?query=TREM2"},"sequence":{"accession":"Q9NZC2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NZC2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NZC2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NZC2"}},"corpus_meta":[{"pmid":"23150934","id":"PMC_23150934","title":"TREM2 variants in Alzheimer's disease.","date":"2012","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23150934","citation_count":2363,"is_preprint":false},{"pmid":"28930663","id":"PMC_28930663","title":"The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.","date":"2017","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28930663","citation_count":2151,"is_preprint":false},{"pmid":"25728668","id":"PMC_25728668","title":"TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25728668","citation_count":1386,"is_preprint":false},{"pmid":"31257031","id":"PMC_31257031","title":"Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner.","date":"2019","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/31257031","citation_count":1025,"is_preprint":false},{"pmid":"28802038","id":"PMC_28802038","title":"TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.","date":"2017","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/28802038","citation_count":949,"is_preprint":false},{"pmid":"31932797","id":"PMC_31932797","title":"Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.","date":"2020","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31932797","citation_count":857,"is_preprint":false},{"pmid":"27477018","id":"PMC_27477018","title":"TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia.","date":"2016","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/27477018","citation_count":715,"is_preprint":false},{"pmid":"24990881","id":"PMC_24990881","title":"TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis.","date":"2014","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24990881","citation_count":637,"is_preprint":false},{"pmid":"16951310","id":"PMC_16951310","title":"Cutting edge: TREM-2 attenuates macrophage activation.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16951310","citation_count":568,"is_preprint":false},{"pmid":"29518356","id":"PMC_29518356","title":"TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function.","date":"2018","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/29518356","citation_count":566,"is_preprint":false},{"pmid":"31902528","id":"PMC_31902528","title":"TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge.","date":"2020","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/31902528","citation_count":556,"is_preprint":false},{"pmid":"30266932","id":"PMC_30266932","title":"TREM2 - a key player in microglial biology and Alzheimer disease.","date":"2018","source":"Nature reviews. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30266932","citation_count":546,"is_preprint":false},{"pmid":"32531244","id":"PMC_32531244","title":"The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32531244","citation_count":475,"is_preprint":false},{"pmid":"30140051","id":"PMC_30140051","title":"Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.","date":"2018","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30140051","citation_count":457,"is_preprint":false},{"pmid":"30617257","id":"PMC_30617257","title":"Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE.","date":"2019","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30617257","citation_count":424,"is_preprint":false},{"pmid":"32783915","id":"PMC_32783915","title":"Coupled scRNA-Seq and Intracellular Protein Activity Reveal an Immunosuppressive Role of TREM2 in Cancer.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32783915","citation_count":391,"is_preprint":false},{"pmid":"30572908","id":"PMC_30572908","title":"New insights into the role of TREM2 in Alzheimer's disease.","date":"2018","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/30572908","citation_count":366,"is_preprint":false},{"pmid":"31590042","id":"PMC_31590042","title":"Curcumin inhibits LPS-induced neuroinflammation by promoting microglial M2 polarization via TREM2/ TLR4/ NF-κB pathways in BV2 cells.","date":"2019","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31590042","citation_count":353,"is_preprint":false},{"pmid":"28442216","id":"PMC_28442216","title":"TREM2, Microglia, and Neurodegenerative Diseases.","date":"2017","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28442216","citation_count":338,"is_preprint":false},{"pmid":"31301936","id":"PMC_31301936","title":"TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease.","date":"2019","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/31301936","citation_count":295,"is_preprint":false},{"pmid":"34686340","id":"PMC_34686340","title":"Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34686340","citation_count":274,"is_preprint":false},{"pmid":"28077724","id":"PMC_28077724","title":"TREM2 Promotes Microglial Survival by Activating Wnt/β-Catenin Pathway.","date":"2017","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28077724","citation_count":269,"is_preprint":false},{"pmid":"32154671","id":"PMC_32154671","title":"Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region.","date":"2020","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32154671","citation_count":242,"is_preprint":false},{"pmid":"28432014","id":"PMC_28432014","title":"TREM2-Ligand Interactions in Health and Disease.","date":"2017","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28432014","citation_count":217,"is_preprint":false},{"pmid":"29361745","id":"PMC_29361745","title":"Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29361745","citation_count":216,"is_preprint":false},{"pmid":"37081148","id":"PMC_37081148","title":"TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer.","date":"2023","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37081148","citation_count":181,"is_preprint":false},{"pmid":"25897174","id":"PMC_25897174","title":"TREM-2 promotes macrophage survival and lung disease after respiratory viral infection.","date":"2015","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25897174","citation_count":172,"is_preprint":false},{"pmid":"36889359","id":"PMC_36889359","title":"TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma.","date":"2023","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/36889359","citation_count":167,"is_preprint":false},{"pmid":"32840654","id":"PMC_32840654","title":"APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.","date":"2020","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/32840654","citation_count":165,"is_preprint":false},{"pmid":"33516818","id":"PMC_33516818","title":"TREM2, microglia, and Alzheimer's disease.","date":"2021","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/33516818","citation_count":162,"is_preprint":false},{"pmid":"35750138","id":"PMC_35750138","title":"Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH.","date":"2022","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35750138","citation_count":162,"is_preprint":false},{"pmid":"36635449","id":"PMC_36635449","title":"TREM2hi resident macrophages protect the septic heart by maintaining cardiomyocyte homeostasis.","date":"2023","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36635449","citation_count":152,"is_preprint":false},{"pmid":"35933399","id":"PMC_35933399","title":"Spatiotemporal dynamics of macrophage heterogeneity and a potential function of Trem2hi macrophages in infarcted hearts.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35933399","citation_count":151,"is_preprint":false},{"pmid":"30930146","id":"PMC_30930146","title":"A Subset of TREM2+ Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth.","date":"2019","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/30930146","citation_count":148,"is_preprint":false},{"pmid":"26337043","id":"PMC_26337043","title":"TREM2 in CNS homeostasis and neurodegenerative disease.","date":"2015","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/26337043","citation_count":137,"is_preprint":false},{"pmid":"29374630","id":"PMC_29374630","title":"Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage.","date":"2018","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/29374630","citation_count":131,"is_preprint":false},{"pmid":"38646596","id":"PMC_38646596","title":"Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis.","date":"2023","source":"Nature cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/38646596","citation_count":124,"is_preprint":false},{"pmid":"30341064","id":"PMC_30341064","title":"High-affinity interactions and signal transduction between Aβ oligomers and TREM2.","date":"2018","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30341064","citation_count":120,"is_preprint":false},{"pmid":"34916658","id":"PMC_34916658","title":"TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration.","date":"2021","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34916658","citation_count":113,"is_preprint":false},{"pmid":"36219197","id":"PMC_36219197","title":"Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading.","date":"2022","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36219197","citation_count":113,"is_preprint":false},{"pmid":"26854967","id":"PMC_26854967","title":"TREM2 Function in Alzheimer's Disease and Neurodegeneration.","date":"2016","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26854967","citation_count":110,"is_preprint":false},{"pmid":"34851693","id":"PMC_34851693","title":"AD-linked R47H-TREM2 mutation induces disease-enhancing microglial states via AKT hyperactivation.","date":"2021","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34851693","citation_count":107,"is_preprint":false},{"pmid":"36056435","id":"PMC_36056435","title":"Trem2 deletion enhances tau dispersion and pathology through microglia exosomes.","date":"2022","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/36056435","citation_count":104,"is_preprint":false},{"pmid":"35867799","id":"PMC_35867799","title":"TREM2 macrophages induced by human lipids drive inflammation in acne lesions.","date":"2022","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35867799","citation_count":103,"is_preprint":false},{"pmid":"35041990","id":"PMC_35041990","title":"Soluble TREM2: Innocent bystander or active player in neurological diseases?","date":"2022","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/35041990","citation_count":98,"is_preprint":false},{"pmid":"32907830","id":"PMC_32907830","title":"TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.","date":"2020","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/32907830","citation_count":97,"is_preprint":false},{"pmid":"37172094","id":"PMC_37172094","title":"TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37172094","citation_count":90,"is_preprint":false},{"pmid":"30548312","id":"PMC_30548312","title":"TREM2 triggers microglial density and age-related neuronal loss.","date":"2018","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/30548312","citation_count":87,"is_preprint":false},{"pmid":"29685286","id":"PMC_29685286","title":"Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease.","date":"2018","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/29685286","citation_count":86,"is_preprint":false},{"pmid":"36368315","id":"PMC_36368315","title":"TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.","date":"2022","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/36368315","citation_count":85,"is_preprint":false},{"pmid":"38974464","id":"PMC_38974464","title":"TREM2 protects from atherosclerosis by limiting necrotic core formation.","date":"2024","source":"Nature cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/38974464","citation_count":81,"is_preprint":false},{"pmid":"27662313","id":"PMC_27662313","title":"Neuroprotective Effect of TREM-2 in Aging and Alzheimer's Disease Model.","date":"2017","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/27662313","citation_count":78,"is_preprint":false},{"pmid":"36107206","id":"PMC_36107206","title":"Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia.","date":"2022","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36107206","citation_count":77,"is_preprint":false},{"pmid":"38182899","id":"PMC_38182899","title":"TREM2 macrophage promotes cardiac repair in myocardial infarction by reprogramming metabolism via SLC25A53.","date":"2024","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/38182899","citation_count":73,"is_preprint":false},{"pmid":"39172787","id":"PMC_39172787","title":"Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/39172787","citation_count":71,"is_preprint":false},{"pmid":"38159572","id":"PMC_38159572","title":"Trem2 expression in microglia is required to maintain normal neuronal bioenergetics during development.","date":"2023","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/38159572","citation_count":68,"is_preprint":false},{"pmid":"38617547","id":"PMC_38617547","title":"TREM2 promotes macrophage polarization from M1 to M2 and suppresses osteoarthritis through the NF-κB/CXCL3 axis.","date":"2024","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38617547","citation_count":68,"is_preprint":false},{"pmid":"33863908","id":"PMC_33863908","title":"TREM2 is a receptor for non-glycosylated mycolic acids of mycobacteria that limits anti-mycobacterial macrophage activation.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33863908","citation_count":68,"is_preprint":false},{"pmid":"37133566","id":"PMC_37133566","title":"TREM2 promotes cholesterol uptake and foam cell formation in atherosclerosis.","date":"2023","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/37133566","citation_count":65,"is_preprint":false},{"pmid":"35750136","id":"PMC_35750136","title":"TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation.","date":"2022","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35750136","citation_count":63,"is_preprint":false},{"pmid":"33628208","id":"PMC_33628208","title":"Trem-2 Promotes Emergence of Restorative Macrophages and Endothelial Cells During Recovery From Hepatic Tissue Damage.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33628208","citation_count":62,"is_preprint":false},{"pmid":"33297569","id":"PMC_33297569","title":"Function of TREM1 and TREM2 in Liver-Related Diseases.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33297569","citation_count":59,"is_preprint":false},{"pmid":"36989543","id":"PMC_36989543","title":"TREM2: A new player in the tumor microenvironment.","date":"2023","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36989543","citation_count":58,"is_preprint":false},{"pmid":"24383713","id":"PMC_24383713","title":"TREM-2 promotes macrophage-mediated eradication of Pseudomonas aeruginosa via a PI3K/Akt pathway.","date":"2014","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24383713","citation_count":57,"is_preprint":false},{"pmid":"38788719","id":"PMC_38788719","title":"Distinct roles of TREM2 in central nervous system cancers and peripheral cancers.","date":"2024","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/38788719","citation_count":54,"is_preprint":false},{"pmid":"25281879","id":"PMC_25281879","title":"What happens to microglial TREM2 in Alzheimer's disease: Immunoregulatory turned into immunopathogenic?","date":"2014","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25281879","citation_count":54,"is_preprint":false},{"pmid":"35746551","id":"PMC_35746551","title":"Exploring the Impact of TREM2 in Tumor-Associated Macrophages.","date":"2022","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/35746551","citation_count":50,"is_preprint":false},{"pmid":"38478630","id":"PMC_38478630","title":"Hepatic danger signaling triggers TREM2+ macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation.","date":"2024","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38478630","citation_count":48,"is_preprint":false},{"pmid":"17966394","id":"PMC_17966394","title":"The enigmatic function of TREM-2 in osteoclastogenesis.","date":"2007","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/17966394","citation_count":44,"is_preprint":false},{"pmid":"34689040","id":"PMC_34689040","title":"Secretases in Alzheimer's disease: Novel insights into proteolysis of APP and TREM2.","date":"2021","source":"Current opinion in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34689040","citation_count":43,"is_preprint":false},{"pmid":"35717259","id":"PMC_35717259","title":"LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions.","date":"2022","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/35717259","citation_count":42,"is_preprint":false},{"pmid":"38020891","id":"PMC_38020891","title":"The role of TREM2 in Alzheimer's disease: from the perspective of Tau.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/38020891","citation_count":40,"is_preprint":false},{"pmid":"36625077","id":"PMC_36625077","title":"TREM2-dependent microglial function is essential for remyelination and subsequent neuroprotection.","date":"2023","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/36625077","citation_count":40,"is_preprint":false},{"pmid":"36119485","id":"PMC_36119485","title":"The therapeutic potential of TREM2 in cancer.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36119485","citation_count":38,"is_preprint":false},{"pmid":"36417868","id":"PMC_36417868","title":"Plaque contact and unimpaired Trem2 is required for the microglial response to amyloid pathology.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36417868","citation_count":38,"is_preprint":false},{"pmid":"38151703","id":"PMC_38151703","title":"TREM2-IGF1 Mediated Glucometabolic Enhancement Underlies Microglial Neuroprotective Properties During Ischemic Stroke.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38151703","citation_count":37,"is_preprint":false},{"pmid":"38769824","id":"PMC_38769824","title":"Microglia, Trem2, and Neurodegeneration.","date":"2024","source":"The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/38769824","citation_count":37,"is_preprint":false},{"pmid":"28365005","id":"PMC_28365005","title":"Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease.","date":"2017","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/28365005","citation_count":36,"is_preprint":false},{"pmid":"40247363","id":"PMC_40247363","title":"TREM2 and sTREM2 in Alzheimer's disease: from mechanisms to therapies.","date":"2025","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/40247363","citation_count":35,"is_preprint":false},{"pmid":"37740498","id":"PMC_37740498","title":"Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.","date":"2024","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37740498","citation_count":35,"is_preprint":false},{"pmid":"34275100","id":"PMC_34275100","title":"Role of TREM2 in Alzheimer's Disease: A Long Road Ahead.","date":"2021","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34275100","citation_count":34,"is_preprint":false},{"pmid":"36805764","id":"PMC_36805764","title":"TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation.","date":"2023","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36805764","citation_count":34,"is_preprint":false},{"pmid":"35781003","id":"PMC_35781003","title":"TREM2 modulates neuroinflammation with elevated IRAK3 expression and plays a neuroprotective role after experimental SAH in rats.","date":"2022","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/35781003","citation_count":34,"is_preprint":false},{"pmid":"37024448","id":"PMC_37024448","title":"TREM2+ and interstitial-like macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37024448","citation_count":33,"is_preprint":false},{"pmid":"35153729","id":"PMC_35153729","title":"Does Soluble TREM2 Protect Against Alzheimer's Disease?","date":"2022","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35153729","citation_count":32,"is_preprint":false},{"pmid":"29889572","id":"PMC_29889572","title":"Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?","date":"2018","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/29889572","citation_count":32,"is_preprint":false},{"pmid":"26001891","id":"PMC_26001891","title":"Variable expression of microglial DAP12 and TREM2 genes in Nasu-Hakola disease.","date":"2015","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/26001891","citation_count":32,"is_preprint":false},{"pmid":"38821351","id":"PMC_38821351","title":"Microglia and TREM2.","date":"2024","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38821351","citation_count":31,"is_preprint":false},{"pmid":"38237157","id":"PMC_38237157","title":"Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.","date":"2024","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38237157","citation_count":31,"is_preprint":false},{"pmid":"37595041","id":"PMC_37595041","title":"TREM2 is down-regulated by HSV1 in microglia and involved in antiviral defense in the brain.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37595041","citation_count":30,"is_preprint":false},{"pmid":"38981007","id":"PMC_38981007","title":"Microglia Gravitate toward Amyloid Plaques Surrounded by Externalized Phosphatidylserine via TREM2.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38981007","citation_count":29,"is_preprint":false},{"pmid":"37641212","id":"PMC_37641212","title":"TREM2 promotes glioma progression and angiogenesis mediated by microglia/brain macrophages.","date":"2023","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/37641212","citation_count":27,"is_preprint":false},{"pmid":"36681358","id":"PMC_36681358","title":"Profiling TREM2 expression in amyotrophic lateral sclerosis.","date":"2023","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36681358","citation_count":27,"is_preprint":false},{"pmid":"33881612","id":"PMC_33881612","title":"TREM2 expression in the brain and biological fluids in prion diseases.","date":"2021","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/33881612","citation_count":27,"is_preprint":false},{"pmid":"32826884","id":"PMC_32826884","title":"TMEM59 interacts with TREM2 and modulates TREM2-dependent microglial activities.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32826884","citation_count":27,"is_preprint":false},{"pmid":"37302170","id":"PMC_37302170","title":"TREM2, microglial and ischemic stroke.","date":"2023","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/37302170","citation_count":25,"is_preprint":false},{"pmid":"39956331","id":"PMC_39956331","title":"TREM2 Depletion in Pancreatic Cancer Elicits Pathogenic Inflammation and Accelerates Tumor Progression via Enriching IL-1β+ Macrophages.","date":"2025","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/39956331","citation_count":24,"is_preprint":false},{"pmid":"36721205","id":"PMC_36721205","title":"Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology.","date":"2023","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/36721205","citation_count":24,"is_preprint":false},{"pmid":"38453910","id":"PMC_38453910","title":"TREM2 deficiency impairs the energy metabolism of Schwann cells and exacerbates peripheral neurological deficits.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38453910","citation_count":24,"is_preprint":false},{"pmid":"36800288","id":"PMC_36800288","title":"Negative regulation of TREM2-mediated C9orf72 poly-GA clearance by the NLRP3 inflammasome.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36800288","citation_count":24,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49110,"output_tokens":10163,"usd":0.149888},"stage2":{"model":"claude-opus-4-6","input_tokens":14180,"output_tokens":5218,"usd":0.302025},"total_usd":0.451913,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"TREM2 signals through the adaptor protein DAP12 and functions to attenuate macrophage activation by inhibiting cytokine production in response to TLR ligands (LPS, zymosan, CpG); TREM2-deficient macrophages produce more cytokines, and TREM2 accounts for the increased cytokine production previously reported in DAP12-deficient macrophages.\",\n      \"method\": \"TREM2 knockout mice, TLR ligand stimulation assays, cytokine measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype, genetic epistasis with DAP12, replicated across multiple TLR ligands\",\n      \"pmids\": [\"16951310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TREM2 transduces intracellular signals through DAP12 and is required for normal osteoclastogenesis; human TREM2/DAP12-deficient pre-osteoclast precursors fail to differentiate into mature osteoclasts with bone resorptive activity in vitro.\",\n      \"method\": \"In vitro osteoclast differentiation assay with human TREM2/DAP12-deficient precursors\",\n      \"journal\": \"Advances in experimental medicine and biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined cellular differentiation phenotype, single lab\",\n      \"pmids\": [\"17966394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TREM2 missense mutations associated with FTD and FTD-like syndrome reduce TREM2 maturation, abolish shedding by ADAM proteases (α-secretases), and impair phagocytic activity; as a consequence of reduced shedding, TREM2 is virtually absent in CSF and plasma of affected patients.\",\n      \"method\": \"Cell-based assays of TREM2 maturation and shedding, phagocytosis assays, CSF/plasma measurement in patients\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (biochemistry, functional phagocytosis, patient biofluid), replicated across mutations\",\n      \"pmids\": [\"24990881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TREM2 promotes macrophage-mediated intracellular killing of Pseudomonas aeruginosa by enhancing reactive oxygen species (ROS) production via the PI3K/Akt signaling pathway; TREM2 silencing inhibits Akt phosphorylation and bacterial killing, whereas PI3K agonism rescues the killing defect.\",\n      \"method\": \"TREM2 siRNA knockdown, overexpression, phagocytosis/killing assays, ROS measurement, PI3K inhibitor/agonist treatments, Western blot for Akt phosphorylation\",\n      \"journal\": \"Scandinavian journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods (KD, OE, pharmacological rescue) in single study\",\n      \"pmids\": [\"24383713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TREM2 senses a broad array of anionic and zwitterionic lipids (damage-associated lipid patterns) associated with fibrillar Aβ in lipid membranes and on damaged neurons; TREM2 deficiency and haploinsufficiency cause dysfunctional microglial clustering around Aβ plaques and microglial apoptosis in the 5XFAD mouse model; the R47H AD-risk mutation impairs TREM2 detection of lipid ligands.\",\n      \"method\": \"5XFAD mouse model with TREM2 KO/haploinsufficiency, lipid-binding assays, microglial clustering and apoptosis analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro lipid-binding assays + mouse model with defined cellular phenotype, high-citation foundational paper\",\n      \"pmids\": [\"25728668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TREM2 promotes macrophage survival; viral replication increases TREM2 levels including the soluble form (sTREM2), and IL-13 and DAP12 promote TREM2 cleavage to sTREM2, which acts in a feed-forward manner to prevent macrophage apoptosis.\",\n      \"method\": \"Mouse model of Sendai virus infection, TREM2 KO mice, measurement of soluble TREM2, apoptosis assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with defined phenotype plus mechanistic sTREM2 characterization, single lab\",\n      \"pmids\": [\"25897174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TREM2 binds lipoprotein particles (LDL) and apolipoproteins (APOE, CLU/APOJ) identified by unbiased protein microarray; TREM2 overexpression enhances uptake of LDL, CLU, and APOE; Aβ-lipoprotein complexes are taken up by microglia in a TREM2-dependent fashion; disease-associated TREM2 mutations abolish or reduce ligand binding and impair uptake.\",\n      \"method\": \"Protein microarray screen, Co-IP/pulldown, overexpression in heterologous cells, Trem2 KO microglia, human macrophage uptake assays\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased screen + multiple functional uptake assays + KO microglia + human cells with disease variant\",\n      \"pmids\": [\"27477018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TREM2 deficiency causes defective mTOR signaling, leading to aberrant autophagy, reduced ATP levels, and impaired biosynthetic pathways in microglia; this metabolic derailment can be rescued in vitro by Dectin-1 (which elicits TREM2-like signals) or cyclocreatine, and dietary cyclocreatine restores microglial clustering and reduces neuronal dystrophy in TREM2-deficient AD mice.\",\n      \"method\": \"Metabolomics + RNA-seq, TREM2-deficient mouse and human AD samples, in vitro rescue experiments, in vivo dietary cyclocreatine treatment\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — metabolomics + transcriptomics + in vitro + in vivo rescue, high-citation paper with orthogonal methods\",\n      \"pmids\": [\"28802038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TREM2 promotes microglial survival by activating the Wnt/β-catenin signaling pathway; TREM2 stabilizes β-catenin by inhibiting its degradation via Akt/GSK3β; TREM2 deficiency reduces viability and proliferation of primary microglia and induces G1/S cell cycle arrest; treatment with Wnt pathway activators (Wnt3a, LiCl, TDZD-8) rescues microglia survival in Trem2-deficient microglia and brain.\",\n      \"method\": \"TREM2 KD/KO in vitro and in vivo, cell viability/proliferation assays, β-catenin stability assays, pharmacological rescue with Wnt agonists\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple KD/KO models + defined signaling mechanism + pharmacological rescue in vitro and in vivo\",\n      \"pmids\": [\"28077724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TREM2 induces APOE signaling and drives a switch from homeostatic to neurodegenerative microglia phenotype after phagocytosis of apoptotic neurons; targeting the TREM2-APOE pathway restores homeostatic microglial signature in ALS and AD mouse models and prevents neuronal loss in acute neurodegeneration models.\",\n      \"method\": \"Mouse models of ALS, MS, AD; microglial transcriptomics; APOE targeting; genetic and pharmacological manipulation\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple disease models + genetic epistasis + defined pathway + replicated across diseases\",\n      \"pmids\": [\"28930663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TREM2 directly binds β-amyloid (Aβ) oligomers with nanomolar affinity; TREM2 deficiency impairs Aβ degradation; Aβ-induced microglial responses (depolarization, K+ current, cytokine expression, migration, proliferation, apoptosis, morphological changes) are TREM2-dependent; Aβ enhances TREM2 interaction with DAP12, regulating downstream phosphorylation of SYK and GSK3β.\",\n      \"method\": \"Direct binding assays, primary microglial culture, mouse brain experiments, Co-IP for TREM2-DAP12, phosphorylation assays for SYK and GSK3β, TREM2 KO mice\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — binding assays + KO + multiple downstream signaling readouts with orthogonal methods\",\n      \"pmids\": [\"29518356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TREM2 interacts directly with various forms of Aβ, with highest affinity for soluble Aβ42 oligomers (slow dissociation); Aβ pre-incubation blocks APOE interaction with TREM2; AD-associated TREM2 variants (R47H, R62H) show equivalent Aβ binding affinity but loss-of-function in terms of downstream NFAT signaling and Aβ42 internalization.\",\n      \"method\": \"Multiple binding assays (SPR, ELISA-based), NFAT reporter assay, Aβ42 internalization assays in cells expressing TREM2 variants\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding reconstitution with multiple assay formats + functional signaling assay\",\n      \"pmids\": [\"30341064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of functional TREM2 increases amyloid plaque seeding due to reduced microglial clustering around newly seeded plaques and reduced plaque-associated ApoE; microglia are identified as one origin of plaque-associated ApoE; longitudinal PET demonstrates accelerated early amyloidogenesis in Trem2 loss-of-function mutants.\",\n      \"method\": \"Trem2 KO mouse models, microglia depletion, proteomic analyses of plaques, longitudinal amyloid small-animal PET, human AD brain analysis\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (proteomics, microglia depletion, in vivo imaging, human validation)\",\n      \"pmids\": [\"30617257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TREM2 is required for TREM2+ lipid-associated macrophage (LAM) transcriptional programming in adipose tissue; genetic ablation of Trem2 inhibits the downstream LAM molecular program, leading to adipocyte hypertrophy, systemic hypercholesterolemia, body fat accumulation, and glucose intolerance.\",\n      \"method\": \"Single-cell RNA sequencing, Trem2 KO mice, metabolic phenotyping\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq + KO with defined metabolic phenotype, high-citation paper\",\n      \"pmids\": [\"31257031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TREM2 acts downstream of CD33 in modulating microglial function: CD33 knockout reduces Aβ pathology in an effect that requires TREM2; genes related to phagocytosis and signaling upregulated in 5xFAD;CD33-/- microglia depend on the presence of TREM2, establishing TREM2 downstream of CD33 by genetic epistasis.\",\n      \"method\": \"Double-knockout mouse models (5xFAD;CD33-/-;TREM2-/-), RNA-seq profiling, epistasis analysis\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple KO combinations + transcriptomics\",\n      \"pmids\": [\"31301936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TREM2-deficient microglia phagocytose myelin debris but fail to clear myelin cholesterol, resulting in pathogenic cholesteryl ester (CE) accumulation; TREM2 acts as a key transcriptional regulator of cholesterol transport and metabolism; CE accumulation is rescued by ACAT1 inhibitor and LXR agonist.\",\n      \"method\": \"Chronic demyelination mouse model, TREM2 KO mice, RNA-seq + lipidomics, human iPSC-derived microglia, pharmacological rescue\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — RNA-seq + lipidomics + mouse model + human iPSC microglia + pharmacological rescue\",\n      \"pmids\": [\"31902528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Genetic ablation of Trem2 in tumor-bearing mice inhibits accumulation of intra-tumoral Arg1+ Trem2+ regulatory myeloid (Mreg) cells, leading to decreased dysfunctional CD8+ T cells and reduced tumor growth, identifying TREM2 as a driver of the immunosuppressive myeloid program in tumors.\",\n      \"method\": \"INs-seq (scRNA-seq + intracellular protein activity), Trem2 KO mouse tumor models, CD8+ T cell functional analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — novel technology + KO with defined immune phenotype in multiple tumor models\",\n      \"pmids\": [\"32783915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Monoclonal antibody 4D9 targeting the TREM2 stalk region stabilizes TREM2 on the cell surface, reduces ADAM10/17-mediated shedding, and concomitantly activates phospho-SYK signaling; in vivo, 4D9 reduced amyloidogenesis and enhanced microglial TREM2 expression in AD mouse model.\",\n      \"method\": \"Antibody panel screening, surface TREM2 quantification, phospho-SYK assay, in vitro phagocytosis assays, in vivo AD mouse model treatment\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic antibody characterization + in vitro signaling + in vivo validation\",\n      \"pmids\": [\"32154671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TREM2 recognizes non-glycosylated mycolic acids (MAs) from mycobacteria via a TREM2/DAP12-dependent but CARD9-independent mechanism; this suppresses anti-mycobacterial immunity by recruiting iNOS-negative, mycobacterium-permissive macrophages; TREM2 deletion enhances Mincle-induced macrophage activation and accelerates mycobacterial elimination, indicating TREM2 is exploited by mycobacteria for immune evasion.\",\n      \"method\": \"Lipid-binding assays, TREM2/DAP12 KO macrophages, in vitro macrophage activation assays, in vivo mycobacterial infection models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct ligand binding + KO macrophages + in vivo infection model with defined phenotype\",\n      \"pmids\": [\"33863908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TREM2 directly interacts with TDP-43 as demonstrated by mass spectrometry and surface plasmon resonance (SPR) in vitro and in vivo; TREM2 deficiency impairs phagocytic clearance of pathological TDP-43 by microglia and enhances neuronal damage; a TREM2-dependent CD11c-high microglial subpopulation with phagocytic activity is induced by human TDP-43.\",\n      \"method\": \"Mass spectrometry, SPR analysis, TREM2-deficient mouse models, mass cytometry, human ALS tissue analysis\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — SPR for direct binding + MS + KO mouse with phenotype + human tissue validation\",\n      \"pmids\": [\"34916658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The R47H TREM2 variant induces hyperactivation of AKT signaling downstream of TREM2; pharmacological AKT inhibition (MK-2206) largely reverses enhanced inflammatory signatures in primary R47H microglia and rescues tauopathy-induced synapse loss in R47H heterozygous tauopathy mice.\",\n      \"method\": \"Human AD snRNA-seq, R47H knock-in tauopathy mouse model, scRNA-seq, pharmacological AKT inhibition with MK-2206\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human AD transcriptomics + knock-in mouse model + pharmacological rescue, conserved across species\",\n      \"pmids\": [\"34851693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TREM2 interacts with TMEM59 (a type I transmembrane protein); TREM2 overexpression reduces TMEM59 protein levels by promoting its degradation; elevated TMEM59 in Trem2-deficient microglia contributes to impaired survival, proliferation, migration, phagocytosis, dysregulated autophagy, and metabolism.\",\n      \"method\": \"Co-IP, overexpression and KO in microglia, protein degradation assays, functional microglial assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP + functional rescue by TMEM59 silencing, single lab\",\n      \"pmids\": [\"32826884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TREM2 deletion enhances tau spreading from the medial entorhinal cortex to hippocampus; Trem2 deletion in microglia enhances intraneuronal tau dispersion via exosomes — Trem2 KO microglia show enhanced tau distribution to endosomal/pre-exosomal compartments and exosomes from Trem2 KO microglia have elevated tau levels and enhanced tau-seeding capacity.\",\n      \"method\": \"AAV-P301L tau injection model, Trem2 KO mice, microfluidic dispersion assay, exosome isolation and characterization, tau FRET reporter assay, proteomic analysis\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vitro and in vivo methods + FRET reporter assay for tau seeding\",\n      \"pmids\": [\"36056435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LILRB2 (an inhibitory receptor with ITIM motifs) co-ligates with TREM2 on shared ligands (Aβ oligomers, phosphatidylserine) and inhibits TREM2 signaling; a LILRB2 antagonist antibody (Ab29) blocks this inhibition, enhancing TREM2 signaling, microglia phagocytosis, migration, and amyloid plaque clearance in vivo in 5XFAD mice.\",\n      \"method\": \"Co-ligation experiments in iPSC-derived microglia, LILRB2 antagonist antibody, phagocytosis and migration assays, in vivo stereotaxic microglia grafting in 5XFAD mice\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic co-ligation + antibody rescue in human iPSC microglia + in vivo validation\",\n      \"pmids\": [\"35717259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TREM2-deficient microglia in TREM2-independent microgliosis context (with ApoE4) show exacerbated tau-mediated neurodegeneration; this is epistatic to ApoE4 — TREM2 KO in P301S/ApoE4 mice worsens, rather than attenuates, neurodegeneration, revealing that TREM2-independent microgliosis facilitates neurodegeneration in the presence of ApoE4.\",\n      \"method\": \"Double-mutant mouse models (P301S tau × ApoE4 × TREM2 KO), transcriptomics, neuropathology\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple KO combinations in well-defined mouse models\",\n      \"pmids\": [\"36368315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2 expression in microglia is required for normal bioenergetic profile of pyramidal neurons during development; in Trem2 KO mice, developing CA1 hippocampal neurons display compromised energetic metabolism, reduced mitochondrial mass, abnormal organelle ultrastructure, and delayed neuronal maturation.\",\n      \"method\": \"Trem2 KO mice, metabolic profiling, electron microscopy of mitochondria, single-cell/nucleus transcriptomics, hippocampal subfield-specific analysis\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mice + ultrastructural analysis + transcriptomics + metabolic profiling with specific regional phenotype\",\n      \"pmids\": [\"38159572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2 splice isoforms (TREM2-222 and TREM2-219) lacking a transmembrane domain are translated and secreted as soluble TREM2 (sTREM2); all sTREM2 species inhibit long-term potentiation (LTP) induction in hippocampal brain slices, and this effect is abolished by GABAA receptor antagonist picrotoxin.\",\n      \"method\": \"In vitro translation and secretion assays, LTP electrophysiology in hippocampal slices, pharmacological blockade with picrotoxin\",\n      \"journal\": \"Genome medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro reconstitution + electrophysiology with pharmacological dissection, single lab\",\n      \"pmids\": [\"36805764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Poly-GA proteins (from C9orf72 GGGGCC repeats) activate the microglial NLRP3 inflammasome to produce IL-1β, which promotes ADAM10-mediated TREM2 cleavage and inhibits phagocytosis of poly-GA; NLRP3 inhibitor MCC950 reduces TREM2 cleavage and poly-GA aggregates, alleviating motor deficits in poly-GA mice.\",\n      \"method\": \"Mouse model of poly-GA aggregation, NLRP3 inhibitor treatment (MCC950), ADAM10 cleavage assays, phagocytosis assays, motor behavioral testing\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway with pharmacological intervention in vivo + defined ADAM10/TREM2 cleavage assay\",\n      \"pmids\": [\"36800288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2 mediates phagocytosis of glioma cells via SYK signaling; TREM2+ myeloid cells display enhanced tumor uptake compared to TREM2- cells, and this phagocytic function is mechanistically linked to TREM2-SYK axis.\",\n      \"method\": \"Single-cell RNA-seq, flow cytometry, in vivo glioma models, in vitro phagocytosis assays with SYK inhibition\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vitro mechanistic assay + in vivo model + human scRNA-seq correlation\",\n      \"pmids\": [\"38237157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2 macrophages suppress NK cell accumulation and cytolytic activity in lung tumors by modulating IL-18/IL-18BP decoy interactions and IL-15 production; Trem2 genetic deletion rescues NK cell accumulation and enables NK cell-mediated tumor regression.\",\n      \"method\": \"Murine lung adenocarcinoma model, Trem2 KO mice, NK cell functional assays, cytokine analysis (IL-18, IL-18BP, IL-15)\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mice + defined molecular mechanism (cytokine axis) + functional NK cell readout\",\n      \"pmids\": [\"37081148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2 is required for antiviral defense in microglia: TREM2 is important for virus-induced IFNB induction through the DNA-sensing cGAS-STING pathway and for phagocytosis of HSV1-infected neurons; TREM2 augments STING signaling and activation of downstream TBK1 and IRF3; TREM2 depletion increases susceptibility to HSV1 infection.\",\n      \"method\": \"hiPSC-derived microglia, TREM2 depletion, HSV1 infection assays, cGAS-STING pathway analysis, microglia-neuron cocultures, mouse brain infection model\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KD in human iPSC microglia + defined signaling pathway + in vivo mouse model\",\n      \"pmids\": [\"37595041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2hi cardiac resident macrophages actively scavenge cardiomyocyte-ejected dysfunctional mitochondria; Trem2 deficiency in macrophages impairs the self-renewal of this subpopulation and results in defective elimination of damaged mitochondria, excessive inflammation, exacerbated cardiac dysfunction, and decreased survival in sepsis.\",\n      \"method\": \"Single-cell RNA-seq, fate mapping, Trem2 KO mouse model of sepsis, mitochondria scavenging assays, intrapericardial cell transfer experiments\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq + fate mapping + KO + cell transfer rescue, multiple orthogonal methods\",\n      \"pmids\": [\"36635449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREM2 deficiency restricts the emergence of lipid-associated macrophages (LAMs) and formation of hepatic crown-like structures; TREM2+ macrophages are superior collagen degraders and required for MASH fibrosis regression; TREM2 imparts protection through phagocytosis, lipid handling, and collagen degradation.\",\n      \"method\": \"scRNA-seq of mouse MASH progression/regression, Trem2 KO mice, collagen degradation assays, lipid handling assays\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — scRNA-seq + KO + functional in vitro assays, orthogonal approaches\",\n      \"pmids\": [\"39172787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Microglia gravitate toward amyloid plaques through TREM2 recognition of externalized phosphatidylserine (ePtdSer) on dystrophic neurons surrounding Aβ plaques; TREM2 loss-of-function (frameshift mutation in exon 2) organoids show reduced TREM2 levels and impaired phagocytic activity toward ePtdSer-positive Aβ plaques.\",\n      \"method\": \"2D/3D/4D co-culture systems, brain organoids with TREM2 loss-of-function mutations, CRISPR-Cas9 APOE4 lines, APPNL-G-F/MAPT double knock-in mice, live imaging of microglial migration\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assay in engineered organoid system + mouse models, single lab\",\n      \"pmids\": [\"38981007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREM2 in macrophages regulates foamy macrophage specification and oxLDL uptake in atherosclerosis; Trem2 loss reduces foamy macrophage ability to take up oxLDL; mechanistically, Trem2-deficient macrophages fail to upregulate cholesterol efflux molecules, resulting in impaired proliferation and survival; myeloid-specific Trem2 deletion attenuates plaque progression.\",\n      \"method\": \"Integrated scRNA-seq trajectory analysis, genome-wide CRISPR screen, myeloid-specific Trem2 KO mice, cholesterol efflux assays, oxLDL uptake assays\",\n      \"journal\": \"Nature cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR screen + KO mouse + functional lipid assays, multiple orthogonal methods\",\n      \"pmids\": [\"38646596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREM2 promotes cholesterol uptake and foam cell formation in atherosclerosis by inhibiting p38 MAPK phosphorylation and PPARγ phosphorylation, thereby increasing PPARγ nuclear transcriptional activity and promoting CD36 scavenger receptor transcription; TREM2 overexpression in SMCs and macrophages increases CD36-dependent lipid influx.\",\n      \"method\": \"ApoE-/- and Trem2-/-/ApoE-/- double KO mice, TREM2 overexpression in primary cells, Western blot for p38/PPARγ phosphorylation, CD36 promoter activity assays\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — KO mouse + overexpression + defined signaling mechanism, single lab\",\n      \"pmids\": [\"37133566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREM2 is essential for efferocytosis capacity of macrophages and survival of lipid-laden macrophages in atherosclerotic lesions; TREM2 deficiency increased necrotic core formation; TREM2 agonism decreased necrotic core formation in early atherosclerosis.\",\n      \"method\": \"Hematopoietic and global TREM2 KO mice in atherosclerosis model, TREM2 agonist treatment, efferocytosis assays, plaque analysis\",\n      \"journal\": \"Nature cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO + agonism + functional efferocytosis assays in vivo and in vitro\",\n      \"pmids\": [\"38974464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CNS-enriched sphingolipids bind TREM2 on myeloid cells in GBM and elicit antitumor responses; TREM2 is immunoprotective in GBM (opposite to peripheral cancers), negatively correlating with immunosuppressive signatures; TREM2 deficiency promotes GBM progression, while AAV-mediated TREM2 overexpression impedes GBM progression.\",\n      \"method\": \"Genetic/pharmacological TREM2 deficiency in vivo, scRNA-seq and spatial sequencing, sphingolipid-TREM2 binding assays, AAV-TREM2 overexpression, anti-PD-1 combination therapy\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct lipid binding + multiple in vivo KO/OE models + single-cell sequencing, orthogonal methods\",\n      \"pmids\": [\"38788719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREM2 promotes macrophage metabolic reprogramming after efferocytosis through the SYK-SMAD4 signaling pathway, which decreases SLC25A53 transcription, impairing NAD+ transport into mitochondria and causing a TCA cycle breakpoint that increases itaconate production; secreted itaconate from TREM2+ macrophages inhibits cardiomyocyte apoptosis and promotes fibroblast proliferation after myocardial infarction.\",\n      \"method\": \"RNA-seq, molecular docking, targeted metabolomics (LC-MS), macrophage-specific TREM2 KO mice, in vitro co-culture experiments\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — metabolomics + RNA-seq + molecular docking + KO mice, single lab with multiple methods\",\n      \"pmids\": [\"38182899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREM2 deficiency in Schwann cells disrupts glycolytic flux and oxidative metabolism, impairs cell proliferation, triggers mitochondrial damage and autophagy via AMPK activation and impaired PI3K-AKT-mTOR signaling; TREM2 deficiency also impairs energy metabolism and axonal growth in sciatic nerve and exacerbates neurological deficits in a mouse model of acute motor axonal neuropathy.\",\n      \"method\": \"TREM2-deficient Schwann cells, metabolomic analysis, AMPK/PI3K-AKT-mTOR pathway analysis, mouse model of AMAN, nerve regeneration assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — metabolomics + signaling pathway analysis + in vivo neuropathy model, single lab\",\n      \"pmids\": [\"38453910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TREM2 functions as a key braking mechanism for the NLRP3/NF-κB/IL-1β inflammasome pathway in tumor-associated macrophages; TREM2 depletion combined with microbial LPS triggers IL-1β upregulation and pathogenic inflammation that fuels pancreatic cancer development; IL-1β inhibition or microbiome ablation reverses accelerated PDAC progression caused by TREM2 depletion.\",\n      \"method\": \"KPPC;Trem2-/- transgenic mouse model of spontaneous PDAC, scRNA-seq, IL-1β inhibition, microbiome ablation experiments\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic mouse model + scRNA-seq + pharmacological and microbiome rescue, multiple orthogonal approaches\",\n      \"pmids\": [\"39956331\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TREM2 is a myeloid cell surface receptor that signals through the adaptor proteins DAP12 (and DAP10) upon binding diverse ligands including anionic lipids, apolipoproteins (APOE, CLU), Aβ oligomers, TDP-43, phosphatidylserine, sphingolipids, and mycolic acids; ligand engagement triggers intracellular SYK phosphorylation and downstream activation of PI3K/Akt, mTOR, Wnt/β-catenin, and AKT/GSK3β pathways, which collectively regulate microglial/macrophage phagocytosis, metabolic fitness (mTOR-dependent energy metabolism and cholesterol handling), survival, proliferation, and inflammatory tone; TREM2 is shed from the cell surface by ADAM10/17 α-secretases to generate soluble sTREM2, and disease-associated mutations (R47H, R62H) impair ligand sensing, TREM2 maturation/shedding, and downstream signaling, thereby impairing the microglial response to Aβ plaques, myelin debris, and other damage-associated patterns across neurodegenerative diseases, metabolic disorders, and cancer.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TREM2 is a myeloid cell surface receptor that senses diverse damage- and pathogen-associated molecular patterns—including anionic lipids, apolipoproteins (APOE, CLU), amyloid-β oligomers, TDP-43, phosphatidylserine, sphingolipids, and mycolic acids—and transduces signals through the adaptor DAP12 to activate SYK, PI3K/Akt, mTOR, and Wnt/β-catenin pathways, thereby governing macrophage and microglial phagocytosis, survival, proliferation, metabolic fitness, and inflammatory calibration [PMID:25728668, PMID:29518356, PMID:28802038, PMID:28077724, PMID:16951310]. TREM2 is proteolytically shed by ADAM10/17 to generate soluble sTREM2, and disease-associated mutations (R47H, R62H) impair ligand binding, receptor maturation/shedding, and downstream signaling, disrupting microglial barrier function around amyloid plaques and myelin debris [PMID:24990881, PMID:30341064, PMID:32154671]. Beyond the CNS, TREM2 programs lipid-associated macrophage (LAM) transcriptional states required for cholesterol handling and efferocytosis in adipose tissue, atherosclerotic lesions, and liver fibrosis, and it modulates anti-tumor immunity in a tissue-context-dependent manner—immunosuppressive in peripheral tumors yet immunoprotective in glioblastoma [PMID:31257031, PMID:38974464, PMID:32783915, PMID:38788719]. Loss-of-function TREM2 mutations cause Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy) and frontotemporal dementia-like syndromes, and the R47H variant is a major genetic risk factor for Alzheimer's disease [PMID:24990881, PMID:34851693].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Establishing TREM2 as an anti-inflammatory brake: TREM2 signals through DAP12 to attenuate TLR-induced cytokine production in macrophages, resolving the question of why DAP12-deficient macrophages are hyperinflammatory.\",\n      \"evidence\": \"TREM2 KO macrophages stimulated with multiple TLR ligands; epistasis with DAP12 KO\",\n      \"pmids\": [\"16951310\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand identity for TREM2 unknown at this point\", \"Mechanism of cytokine suppression downstream of DAP12 unresolved\", \"Tissue-specific roles beyond macrophages untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating TREM2/DAP12 signaling is required for osteoclast differentiation extended TREM2 function beyond inflammation to myeloid cell fate decisions.\",\n      \"evidence\": \"In vitro osteoclastogenesis from human TREM2/DAP12-deficient precursors\",\n      \"pmids\": [\"17966394\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single in vitro system without in vivo bone phenotype characterization\", \"Downstream differentiation signals not identified\", \"Unclear if TREM2 vs DAP12 deficiency is rate-limiting\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linking disease mutations to molecular mechanism: FTD-associated TREM2 missense mutations abolish ADAM protease-mediated shedding, reduce maturation, and impair phagocytosis, explaining the near-absence of sTREM2 in patient biofluids.\",\n      \"evidence\": \"Cell-based TREM2 maturation/shedding assays, phagocytosis assays, CSF/plasma sTREM2 measurement in patients\",\n      \"pmids\": [\"24990881\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of ADAM10 vs ADAM17 as dominant sheddase not disambiguated\", \"Whether shedding loss is cause or correlate of neurodegeneration unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying PI3K/Akt as a key intracellular effector: TREM2 promotes bacterial killing through PI3K/Akt-dependent ROS production, establishing the first defined signaling axis downstream of TREM2.\",\n      \"evidence\": \"siRNA knockdown and overexpression in macrophages, PI3K agonist rescue of killing defect\",\n      \"pmids\": [\"24383713\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single pathogen system\", \"No direct demonstration of TREM2–PI3K physical interaction\", \"SYK involvement not yet tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying TREM2's physiological ligands: TREM2 senses anionic and zwitterionic lipids on damaged neurons and Aβ-associated membranes; TREM2 deficiency causes failed microglial clustering around plaques and microglial apoptosis in AD mice, with R47H impairing lipid detection.\",\n      \"evidence\": \"Lipid-binding assays, 5XFAD mice with TREM2 KO/haploinsufficiency, microglial imaging\",\n      \"pmids\": [\"25728668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of lipid recognition unknown\", \"Which specific lipid species dominate in vivo undetermined\", \"Contribution of protein vs lipid ligands to in vivo phenotype unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"sTREM2 identified as a bioactive species: IL-13 and DAP12 promote TREM2 cleavage, and the resulting sTREM2 acts in a feed-forward manner to prevent macrophage apoptosis during viral infection.\",\n      \"evidence\": \"TREM2 KO mice with Sendai virus, sTREM2 measurement, apoptosis assays\",\n      \"pmids\": [\"25897174\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor for sTREM2 not identified\", \"Single viral infection model\", \"Whether sTREM2 signals through same or different receptor unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Apolipoprotein binding expanded TREM2 ligand repertoire: unbiased screen identified APOE and CLU as TREM2 ligands; TREM2 mediates uptake of Aβ-lipoprotein complexes, and disease mutations impair this binding and uptake.\",\n      \"evidence\": \"Protein microarray, Co-IP, overexpression uptake assays, Trem2 KO microglia, human macrophage assays\",\n      \"pmids\": [\"27477018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TREM2 binds lipidated vs free APOE differently not resolved\", \"Relative contribution of lipid vs protein moieties in lipoprotein recognition unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Three converging studies established TREM2's role in microglial metabolic fitness, survival via Wnt/β-catenin, and the TREM2-APOE axis for microglial state switching: TREM2 deficiency causes mTOR-dependent metabolic derailment with reduced ATP and aberrant autophagy; TREM2 stabilizes β-catenin via Akt/GSK3β to promote survival; and TREM2 drives APOE signaling to switch microglia from homeostatic to neurodegenerative phenotype.\",\n      \"evidence\": \"Metabolomics/RNA-seq with cyclocreatine rescue in AD mice; β-catenin stability and Wnt agonist rescue in KO microglia; transcriptomics in ALS/AD/MS mouse models with APOE pathway targeting\",\n      \"pmids\": [\"28802038\", \"28077724\", \"28930663\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TREM2 engages mTOR mechanistically not fully resolved\", \"Whether Wnt/β-catenin and mTOR axes operate independently or converge unclear\", \"Causal direction between TREM2 and APOE induction in disease not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Direct nanomolar Aβ binding and signaling cascade defined: TREM2 binds Aβ oligomers directly with high affinity; engagement enhances TREM2-DAP12 association and triggers SYK/GSK3β phosphorylation; R47H/R62H variants retain Aβ binding but lose downstream signaling and internalization capacity.\",\n      \"evidence\": \"SPR, ELISA, NFAT reporter, internalization assays, Co-IP for TREM2-DAP12, phosphorylation assays in KO microglia\",\n      \"pmids\": [\"29518356\", \"30341064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of how R47H retains Aβ binding yet loses signaling unknown\", \"Relative importance of Aβ vs lipid ligands in AD pathogenesis not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"TREM2 established as a master regulator of lipid-associated macrophage (LAM) programs and amyloid plaque containment: TREM2 loss increases amyloid seeding due to failed microglial plaque barrier; in adipose tissue, TREM2 is required for LAM transcriptional programming, and its loss causes metabolic syndrome.\",\n      \"evidence\": \"Trem2 KO mice with longitudinal amyloid PET and plaque proteomics; scRNA-seq of adipose macrophages with metabolic phenotyping; genetic epistasis with CD33\",\n      \"pmids\": [\"30617257\", \"31257031\", \"31301936\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LAM programming is identical across tissues undetermined\", \"CD33-TREM2 physical interaction not demonstrated\", \"Whether metabolic phenotype is cell-autonomous or paracrine unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"TREM2 controls cholesterol metabolism after myelin phagocytosis and shapes tumor immunity: TREM2-deficient microglia accumulate toxic cholesteryl esters after demyelination; in tumors, TREM2 drives immunosuppressive myeloid programming that suppresses CD8+ T cell function; anti-TREM2 antibody 4D9 stabilizes surface TREM2 and activates SYK signaling in vivo.\",\n      \"evidence\": \"RNA-seq/lipidomics with iPSC microglia and demyelination model; INs-seq in Trem2 KO tumor models; antibody characterization with phospho-SYK and in vivo AD model treatment\",\n      \"pmids\": [\"31902528\", \"32783915\", \"32154671\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cholesterol handling defect is specific to myelin-derived cholesterol unknown\", \"Tumor context-dependency of TREM2 immunosuppressive role not explained mechanistically\", \"Long-term in vivo effects of anti-shedding antibodies not assessed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Expanding ligand repertoire and variant signaling: TREM2 directly binds mycolic acids and TDP-43, and R47H hyperactivates AKT, which can be therapeutically targeted to rescue tauopathy-associated synapse loss.\",\n      \"evidence\": \"SPR/MS for TDP-43 binding with KO mice; lipid-binding assays for mycolic acids with in vivo mycobacterial infection; R47H knock-in tauopathy mice with AKT inhibitor MK-2206 rescue\",\n      \"pmids\": [\"33863908\", \"34916658\", \"34851693\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TDP-43 is a physiological TREM2 ligand in living brain unclear\", \"How R47H causes AKT hyperactivation while losing other signaling functions paradoxical and unresolved\", \"TMEM59 interaction validation limited to single Co-IP study\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"TREM2 constrains tau spreading and is counter-regulated by LILRB2: TREM2 deletion enhances exosome-mediated tau propagation; LILRB2 co-ligates with TREM2 on shared ligands to inhibit TREM2 signaling, and LILRB2 blockade rescues microglial phagocytosis and plaque clearance.\",\n      \"evidence\": \"AAV-tau injection in Trem2 KO mice with exosome tau FRET reporter; LILRB2 antagonist antibody in iPSC microglia and 5XFAD mice\",\n      \"pmids\": [\"36056435\", \"35717259\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LILRB2-TREM2 crosstalk operates in non-AD contexts unknown\", \"Mechanism by which TREM2 controls exosome tau sorting not identified\", \"ApoE4 epistasis with TREM2 in tau spreading not fully resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"TREM2 function extended to cardiac, hepatic, antiviral, developmental, and tumor contexts: TREM2+ cardiac macrophages scavenge damaged mitochondria; TREM2 is required for MASH fibrosis regression via collagen degradation; TREM2 augments cGAS-STING antiviral signaling; TREM2 is needed for neuronal metabolic maturation during development; and TREM2+ macrophages suppress NK cells in lung tumors via IL-18BP/IL-15 axis.\",\n      \"evidence\": \"Trem2 KO in sepsis/cardiac models, MASH regression models with scRNA-seq, iPSC microglia with HSV1 infection, developmental Trem2 KO with electron microscopy and metabolomics, lung adenocarcinoma KO models\",\n      \"pmids\": [\"36635449\", \"39172787\", \"37595041\", \"38159572\", \"37081148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cardiac and hepatic TREM2 ligands differ from CNS ligands unknown\", \"cGAS-STING augmentation mechanism not defined at the molecular level\", \"How microglial TREM2 non-cell-autonomously controls neuronal mitochondria during development unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"sTREM2 splice isoforms and NLRP3-driven shedding revealed new regulatory layers: alternatively spliced TREM2 isoforms lacking transmembrane domains are secreted and inhibit LTP via a GABAA-dependent mechanism; poly-GA aggregates activate NLRP3/IL-1β to promote ADAM10-mediated TREM2 shedding.\",\n      \"evidence\": \"In vitro translation/secretion assays, hippocampal slice LTP with picrotoxin rescue; poly-GA mouse model with NLRP3 inhibitor MCC950\",\n      \"pmids\": [\"36805764\", \"36800288\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor for sTREM2 in LTP modulation unidentified\", \"Mechanism linking sTREM2 to GABAA signaling unknown\", \"Whether NLRP3-driven shedding is generalizable beyond C9orf72 context unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"TREM2 in cardiovascular disease and cancer refined: TREM2 programs foamy macrophage specification and efferocytosis in atherosclerosis; TREM2 drives post-efferocytosis metabolic reprogramming via SYK-SMAD4-itaconate in myocardial infarction; CNS-enriched sphingolipids activate TREM2 to mount anti-tumor responses in GBM, opposite to peripheral tumors.\",\n      \"evidence\": \"CRISPR screens and myeloid-specific KO in atherosclerosis; metabolomics with macrophage-specific KO in MI; sphingolipid binding assays with AAV-TREM2 in GBM models\",\n      \"pmids\": [\"38646596\", \"38974464\", \"38182899\", \"38788719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural determinants of sphingolipid vs other lipid recognition not resolved\", \"Why TREM2 is immunosuppressive in peripheral tumors but immunoprotective in GBM remains mechanistically unexplained\", \"Whether itaconate production is a universal post-efferocytosis output unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"TREM2 identified as a key brake on NLRP3/NF-κB/IL-1β inflammasome in tumor-associated macrophages: TREM2 depletion combined with microbial LPS unleashes IL-1β-driven pathogenic inflammation that accelerates pancreatic cancer.\",\n      \"evidence\": \"KPPC;Trem2-/- spontaneous PDAC model with scRNA-seq, IL-1β inhibition and microbiome ablation rescue\",\n      \"pmids\": [\"39956331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TREM2 directly inhibits NLRP3 assembly or acts upstream unclear\", \"Microbiome composition changes in TREM2 KO not defined\", \"Generalizability to other GI cancers untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of TREM2's promiscuous ligand recognition; the receptor and signaling mechanism for soluble sTREM2; why TREM2 exerts opposing immunological roles in CNS versus peripheral tumors; and how TREM2 non-cell-autonomously regulates neuronal metabolism during development.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of TREM2 with lipid or protein ligands\", \"sTREM2 receptor unknown\", \"Tissue-context determinants of pro- vs anti-inflammatory TREM2 output undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 4, 10, 11]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [4, 18, 37]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 16, 40]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [6, 15, 34]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 4, 10, 17]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 5, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 16, 18, 29, 30]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 7, 8, 10, 20]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [7, 15, 34, 35]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 5, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 22, 24]}\n    ],\n    \"complexes\": [\n      \"TREM2/DAP12\"\n    ],\n    \"partners\": [\n      \"TYROBP\",\n      \"APOE\",\n      \"CLU\",\n      \"SYK\",\n      \"ADAM10\",\n      \"LILRB2\",\n      \"TMEM59\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}